

# Javed Butler

## List of Publications by Year in Descending Order

**Source:** <https://exaly.com/author-pdf/1284958/javed-butler-publications-by-year.pdf>

**Version:** 2024-04-24

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

496  
papers

28,241  
citations

64  
h-index

160  
g-index

591  
ext. papers

41,707  
ext. citations

8.2  
avg, IF

7.2  
L-index

#	Paper	IF	Citations
496	Annals for Hospitalists Inpatient Notes - Clinical Pearls-Stopping, Starting, and Optimizing Guideline-Directed Medical Therapy in Patients Hospitalized for Heart Failure With Reduced Ejection Fraction.. <i>Annals of Internal Medicine</i> , <b>2022</b> , 175, HO2-HO3	8	
495	Robustness of outcomes in trials evaluating sodium-glucose co-transporter 2 inhibitors for heart failure.. <i>ESC Heart Failure</i> , <b>2022</b> ,	3.7	1
494	Preventing heart failure: a position paper of the Heart Failure Association in collaboration with the European Association of Preventive Cardiology.. <i>European Journal of Heart Failure</i> , <b>2022</b> , 24, 143-168	12.3	7
493	Stress Cardiac Biomarkers, Cardiovascular and Renal Outcomes, and Response to Canagliflozin.. <i>Journal of the American College of Cardiology</i> , <b>2022</b> , 79, 432-444	15.1	2
492	Optimal Background Pharmacological Therapy for Heart Failure Patients in Clinical Trials: JACC Review Topic of the Week.. <i>Journal of the American College of Cardiology</i> , <b>2022</b> , 79, 504-510	15.1	0
491	Cost and Value in Contemporary Heart Failure Clinical Guidance Documents.. <i>JACC: Heart Failure</i> , <b>2022</b> , 10, 1-11	7.9	0
490	Potential Role and Limitations of Estimated Glomerular Filtration Rate Slope Assessment in Cardiovascular Trials: A Review.. <i>JAMA Cardiology</i> , <b>2022</b> ,	16.2	3
489	Early Benefit with Empagliflozin in Heart Failure with Preserved Ejection Fraction Insights from the EMPEROR-Preserved Trial.. <i>European Journal of Heart Failure</i> , <b>2022</b> ,	12.3	4
488	Mineralocorticoid Receptor Antagonists and Empagliflozin in Patients With Heart Failure and Preserved Ejection Fraction.. <i>Journal of the American College of Cardiology</i> , <b>2022</b> , 79, 1129-1137	15.1	1
487	Frailty, Guideline-Directed Medical Therapy, and Outcomes in HF rEF: From the GUIDE-IT Trial.. <i>JACC: Heart Failure</i> , <b>2022</b> , 10, 266-275	7.9	1
486	Trends in HF Hospitalizations Among Young Adults in the United States From 2004 to 2018.. <i>JACC: Heart Failure</i> , <b>2022</b> , 10, 350-362	7.9	0
485	Advances in Our Clinical Understanding of Autonomic Regulation Therapy Using Vagal Nerve Stimulation in Patients Living With Heart Failure.. <i>Frontiers in Physiology</i> , <b>2022</b> , 13, 857538	4.6	1
484	Sodium-glucose co-transporter 2 inhibitors as an early, first line therapy in patients with heart failure and reduced ejection fraction. <i>European Journal of Heart Failure</i> , <b>2021</b> ,	12.3	9
483	DCRM Multispecialty Practice Recommendations for the management of diabetes, cardiorenal, and metabolic diseases.. <i>Journal of Diabetes and Its Complications</i> , <b>2021</b> , 36, 108101	3.2	2
482	Effect of empagliflozin in patients with heart failure across the spectrum of left ventricular ejection fraction. <i>European Heart Journal</i> , <b>2021</b> ,	9.5	26
481	Time is prognosis in heart failure: time-to-treatment initiation as a modifiable risk factor. <i>ESC Heart Failure</i> , <b>2021</b> , 8, 4444	3.7	4
480	Incorporation of natriuretic peptides with clinical risk scores to predict heart failure among individuals with dysglycaemia. <i>European Journal of Heart Failure</i> , <b>2021</b> ,	12.3	2

479	In-Hospital Initiation of Sodium-Glucose Cotransporter-2 Inhibitors for Heart Failure With Reduced Ejection Fraction. <i>Journal of the American College of Cardiology</i> , <b>2021</b> , 78, 2004-2012	15.1	7
478	Changes in inferior vena cava area represent a more sensitive metric than change in filling pressures during experimental manipulation of intravascular volume and tone. <i>European Journal of Heart Failure</i> , <b>2021</b> ,	12.3	2
477	Identifying patients at increased risk for poor outcomes from heart failure with reduced ejection fraction: the PROMPT-HF risk model. <i>ESC Heart Failure</i> , <b>2021</b> ,	3.7	1
476	Empagliflozin in the treatment of heart failure with reduced ejection fraction in addition to background therapies and therapeutic combinations (EMPEROR-Reduced): a post-hoc analysis of a randomised, double-blind trial. <i>Lancet Diabetes and Endocrinology</i> , <b>2021</b> ,	18.1	3
475	Aspirin use is associated with increased risk for incident heart failure: a patient-level pooled analysis. <i>ESC Heart Failure</i> , <b>2021</b> ,	3.7	1
474	Patiromer for the management of hyperkalaemia in patients receiving renin-angiotensin-aldosterone system inhibitors for heart failure: design and rationale of the DIAMOND trial. <i>European Journal of Heart Failure</i> , <b>2021</b> , 24, 230	12.3	4
473	Contextualizing Risk Among Patients With Heart Failure. <i>JAMA - Journal of the American Medical Association</i> , <b>2021</b> ,	27.4	2
472	Empagliflozin, Health Status, and Quality of Life in Patients with Heart Failure and Preserved Ejection Fraction: The EMPEROR-Preserved Trial. <i>Circulation</i> , <b>2021</b> ,	16.7	12
471	Risk Adjustment Model for Preserved Health Status in Patients With Heart Failure and Reduced Ejection Fraction: The CHAMP-HF Registry. <i>Circulation: Cardiovascular Quality and Outcomes</i> , <b>2021</b> , 14, e008072	5.8	0
470	Sex Disparity Among Canadian Cardiologists in Academic Medicine: Differences in Scholarly Productivity and Academic Rank. <i>Cureus</i> , <b>2021</b> , 13, e18687	1.2	
469	Diuretic Changes, Health Care Resource Utilization, and Clinical Outcomes for Heart Failure With Reduced Ejection Fraction: From the Change the Management of Patients With Heart Failure Registry. <i>Circulation: Heart Failure</i> , <b>2021</b> , 14, e008351	7.6	2
468	Prevalence and Prognostic Implications of Diabetes With Cardiomyopathy in Community-Dwelling Adults. <i>Journal of the American College of Cardiology</i> , <b>2021</b> , 78, 1587-1598	15.1	3
467	Effect of empagliflozin on exercise ability and symptoms in heart failure patients with reduced and preserved ejection fraction, with and without type 2 diabetes. <i>European Heart Journal</i> , <b>2021</b> , 42, 700-710	9.5	35
466	The effect of intravenous ferric carboxymaltose on health-related quality of life in iron-deficient patients with acute heart failure: the results of the AFFIRM-AHF study. <i>European Heart Journal</i> , <b>2021</b> ,	9.5	17
465	Disparities in Discharge Disposition After Hospitalizations for Decompensated Heart Failure. <i>Cardiovascular Revascularization Medicine</i> , <b>2021</b> , 28, 95-97	1.6	1
464	Novel Therapies in Heart Failure with Reduced Ejection Fraction: from Soluble Guanylyl Cyclase Stimulators to Cardiac Myosin Activators. <i>Current Treatment Options in Cardiovascular Medicine</i> , <b>2021</b> , 23, 1	2.1	
463	Interplay of Mineralocorticoid Receptor Antagonists and Empagliflozin in Heart Failure: EMPEROR-Reduced. <i>Journal of the American College of Cardiology</i> , <b>2021</b> , 77, 1397-1407	15.1	32
462	Use of sodium-glucose co-transporter 2 inhibitors in patients with heart failure and type 2 diabetes mellitus: data from the Swedish Heart Failure Registry. <i>European Journal of Heart Failure</i> , <b>2021</b> , 23, 1012-1022	12.3	10

461	Effect of Carillon Mitral Contour System on patient-reported outcomes in functional mitral regurgitation: an individual participant data meta-analysis. <i>ESC Heart Failure</i> , <b>2021</b> , 8, 1885-1891	3.7	1
460	Electroanatomic Ratios and Mortality in Patients With Heart Failure: Insights from the ASIAN-HF Registry. <i>Journal of the American Heart Association</i> , <b>2021</b> , 10, e017932	6	1
459	Empagliflozin in Patients With Heart Failure, Reduced Ejection Fraction, and Volume Overload: EMPEROR-Reduced Trial. <i>Journal of the American College of Cardiology</i> , <b>2021</b> , 77, 1381-1392	15.1	30
458	Cigarette Smoking, Incident Coronary Heart Disease, and Coronary Artery Calcification in Black Adults: The Jackson Heart Study. <i>Journal of the American Heart Association</i> , <b>2021</b> , 10, e017320	6	3
457	Resource utilization and costs among patients with heart failure with reduced ejection fraction following a worsening heart failure event. <i>ESC Heart Failure</i> , <b>2021</b> , 8, 1915-1923	3.7	1
456	Universal definition and classification of heart failure: a report of the Heart Failure Society of America, Heart Failure Association of the European Society of Cardiology, Japanese Heart Failure Society and Writing Committee of the Universal Definition of Heart Failure: Endorsed by the Canadian Heart Failure Society, Heart Failure Association of India, Cardiac Society of Australia and	12.3	143
455	Development and validation of optimal phenomapping methods to estimate long-term atherosclerotic cardiovascular disease risk in patients with type 2 diabetes. <i>Diabetologia</i> , <b>2021</b> , 64, 1583-1594	10.3	5
454	Advanced cancer is also a heart failure syndrome: a hypothesis. <i>Journal of Cachexia, Sarcopenia and Muscle</i> , <b>2021</b> , 12, 533-537	10.3	8
453	Therapeutic Manipulation of Myocardial Metabolism: JACC State-of-the-Art Review. <i>Journal of the American College of Cardiology</i> , <b>2021</b> , 77, 2022-2039	15.1	7
452	Prognostic Role of Prior Heart Failure Hospitalization Among Patients Hospitalized for Worsening Chronic Heart Failure. <i>Circulation: Heart Failure</i> , <b>2021</b> , 14, e007871	7.6	4
451	Current and Future Drug and Device Therapies for Pediatric Heart Failure Patients: Potential Lessons from Adult Trials. <i>Children</i> , <b>2021</b> , 8,	2.8	1
450	Thromboembolism in Heart Failure Patients in Sinus Rhythm: Epidemiology, Pathophysiology, Clinical Trials, and Future Direction. <i>JACC: Heart Failure</i> , <b>2021</b> , 9, 243-253	7.9	4
449	Universal Definition and Classification of Heart Failure. <i>Journal of Cardiac Failure</i> , <b>2021</b> ,	3.3	84
448	Meta-Analysis of Efficacy of Sacubitril/Valsartan in Heart Failure With Preserved Ejection Fraction. <i>American Journal of Cardiology</i> , <b>2021</b> , 145, 165-168	3	3
447	Physical Activity, Inflammation, Coronary Artery Calcification, and Incident Coronary Heart Disease in African Americans: Insights From the Jackson Heart Study. <i>Mayo Clinic Proceedings</i> , <b>2021</b> , 96, 901-911	6.4	2
446	Trends in 30- and 90-Day Readmission Rates for Heart Failure. <i>Circulation: Heart Failure</i> , <b>2021</b> , 14, e008335	3.5	15
445	The Reply. <i>American Journal of Medicine</i> , <b>2021</b> , 134, e357	2.4	
444	SGLT-2 Inhibitors in Heart Failure: Guide for Prescribing and Future Perspectives. <i>Current Cardiology Reports</i> , <b>2021</b> , 23, 59	4.2	0

443	Can we trust a smartwatch ECG? Potential and limitations. <i>European Journal of Heart Failure</i> , <b>2021</b> , 23, 850-853	12.3	2
442	Impact of Percutaneous Coronary Intervention on Outcomes in Patients With Heart Failure: JACC State-of-the-Art Review. <i>Journal of the American College of Cardiology</i> , <b>2021</b> , 77, 2432-2447	15.1	5
441	Comparison of New York Heart Association Class and Patient-Reported Outcomes for Heart Failure With Reduced Ejection Fraction. <i>JAMA Cardiology</i> , <b>2021</b> , 6, 522-531	16.2	6
440	Variation in use and dosing escalation of renin angiotensin system, mineralocorticoid receptor antagonist, angiotensin receptor neprilysin inhibitor and beta-blocker therapies in heart failure and reduced ejection fraction: Association of comorbidities. <i>American Heart Journal</i> , <b>2021</b> , 235, 82-96	4.9	1
439	Randomized Placebo-Controlled Trial of Ferric Carboxymaltose in Heart Failure With Iron Deficiency: Rationale and Design. <i>Circulation: Heart Failure</i> , <b>2021</b> , 14, e008100	7.6	4
438	Effect of Obesity on Response to Spironolactone in Patients With Heart Failure With Preserved Ejection Fraction. <i>American Journal of Cardiology</i> , <b>2021</b> , 146, 36-47	3	7
437	Prefrailty, impairment in physical function, and risk of incident heart failure among older adults. <i>Journal of the American Geriatrics Society</i> , <b>2021</b> , 69, 2486-2497	5.6	2
436	Sex Differences in Clinical Course and Patient-Reported Outcomes Among Patients Hospitalized for Heart Failure. <i>JACC: Heart Failure</i> , <b>2021</b> , 9, 336-345	7.9	6
435	What can heart failure trialists learn from oncology trialists?. <i>European Heart Journal</i> , <b>2021</b> , 42, 2373-2383	9.5	4
434	Renal function and the effects of vericiguat in patients with worsening heart failure with reduced ejection fraction: insights from the VICTORIA (Vericiguat Global Study in Subjects with HFrEF) trial. <i>European Journal of Heart Failure</i> , <b>2021</b> , 23, 1313-1321	12.3	15
433	Association Between Angiotensin Receptor-Neprilysin Inhibition, Cardiovascular Biomarkers, and Cardiac Remodeling in Heart Failure With Reduced Ejection Fraction. <i>Circulation: Heart Failure</i> , <b>2021</b> , 14, e008410	7.6	3
432	Dosing of losartan in men versus women with heart failure with reduced ejection fraction: the HEAAL trial. <i>European Journal of Heart Failure</i> , <b>2021</b> , 23, 1477-1484	12.3	1
431	Regional and ethnic influences on the response to empagliflozin in patients with heart failure and a reduced ejection fraction: the EMPEROR-Reduced trial. <i>European Heart Journal</i> , <b>2021</b> , 42, 4442-4451	9.5	6
430	Concentration-dependent clinical and prognostic importance of high-sensitivity cardiac troponin T in heart failure and a reduced ejection fraction and the influence of empagliflozin: the EMPEROR-Reduced trial. <i>European Journal of Heart Failure</i> , <b>2021</b> , 23, 1529-1538	12.3	7
429	Sodium-Glucose Cotransporter-2 Inhibitors in Heart Failure: Racial Differences and a Potential for Reducing Disparities. <i>Circulation</i> , <b>2021</b> , 143, 2329-2331	16.7	3
428	Treatment patterns and clinical outcomes among patients. <i>European Journal of Heart Failure</i> , <b>2021</b> , 23, 1334-1342	12.3	3
427	Paradigm shift in heart failure treatment: are cardiologists ready to use gliflozins?. <i>Heart Failure Reviews</i> , <b>2021</b> , 1	5	2
426	Interleukin-6 and Outcomes in Acute Heart Failure: An ASCEND-HF Substudy. <i>Journal of Cardiac Failure</i> , <b>2021</b> , 27, 670-676	3.3	3

425	Percutaneous Mitral Valve Annuloplasty in Patients With Secondary Mitral Regurgitation and Severe Left Ventricular Enlargement. <i>JACC: Heart Failure</i> , <b>2021</b> , 9, 453-462	7.9	0
424	Development and Validation of Machine Learning-Based Race-Specific Models to Predict 10-Year Risk of Heart Failure: A Multicohort Analysis. <i>Circulation</i> , <b>2021</b> , 143, 2370-2383	16.7	13
423	Representativeness of the VICTORIA Trial Population in Clinical Practice: Analysis of the PINNACLE Registry. <i>Journal of Cardiac Failure</i> , <b>2021</b> , 27, 1374-1381	3.3	4
422	Dietary interventions and nutritional supplements for heart failure: a systematic appraisal and evidence map. <i>European Journal of Heart Failure</i> , <b>2021</b> , 23, 1468-1476	12.3	6
421	Finerenone Reduces New-Onset Atrial Fibrillation in Patients With Chronic Kidney Disease and Type 2 Diabetes. <i>Journal of the American College of Cardiology</i> , <b>2021</b> , 78, 142-152	15.1	17
420	Vericiguat in patients with atrial fibrillation and heart failure with reduced ejection fraction: insights from the VICTORIA trial. <i>European Journal of Heart Failure</i> , <b>2021</b> , 23, 1300-1312	12.3	13
419	Sodium-glucose co-transporter 2 inhibitors in heart failure with preserved ejection fraction: reasons for optimism. <i>European Journal of Heart Failure</i> , <b>2021</b> , 23, 1250-1255	12.3	8
418	Implantable Cardioverter-Defibrillator Eligibility After Initiation of Sacubitril/Valsartan in Chronic Heart Failure: Insights From PROVE-HF. <i>Circulation</i> , <b>2021</b> , 144, 180-182	16.7	7
417	Simultaneous or Rapid Sequence Initiation of Quadruple Medical Therapy for Heart Failure—Optimizing Therapy With the Need for Speed. <i>JAMA Cardiology</i> , <b>2021</b> , 6, 743-744	16.2	30
416	Trends in Substance Abuse Disorders Among Patients Hospitalized for Heart Failure in the United States. <i>Circulation: Heart Failure</i> , <b>2021</b> , 14, e008147	7.6	0
415	Long-term safety and efficacy of sodium zirconium cyclosilicate for hyperkalaemia in patients with mild/moderate versus severe/end-stage chronic kidney disease: comparative results from an open-label, Phase 3 study. <i>Nephrology Dialysis Transplantation</i> , <b>2021</b> , 36, 137-150	4.3	14
414	Effect of Empagliflozin on the Clinical Stability of Patients With Heart Failure and a Reduced Ejection Fraction: The EMPEROR-Reduced Trial. <i>Circulation</i> , <b>2021</b> , 143, 326-336	16.7	74
413	Cardiac and Kidney Benefits of Empagliflozin in Heart Failure Across the Spectrum of Kidney Function: Insights From EMPEROR-Reduced. <i>Circulation</i> , <b>2021</b> , 143, 310-321	16.7	55
412	Atrial Natriuretic Peptide and Treatment With Sacubitril/Valsartan in Heart Failure With Reduced Ejection Fraction. <i>JACC: Heart Failure</i> , <b>2021</b> , 9, 127-136	7.9	17
411	Advanced cancer is also a heart failure syndrome: a hypothesis. <i>European Journal of Heart Failure</i> , <b>2021</b> , 23, 140-144	12.3	4
410	Temporal trends in risk profiles among patients hospitalized for heart failure. <i>American Heart Journal</i> , <b>2021</b> , 232, 154-163	4.9	3
409	Reporting and interpretation of subgroup analyses in heart failure randomized controlled trials. <i>ESC Heart Failure</i> , <b>2021</b> , 8, 26-36	3.7	2
408	Effect of a Self-care Intervention on 90-Day Outcomes in Patients With Acute Heart Failure Discharged From the Emergency Department: A Randomized Clinical Trial. <i>JAMA Cardiology</i> , <b>2021</b> , 6, 200-208	16.2	8

407	Ventricular tachycardia, premature ventricular contractions, and mortality in unselected patients with lung, colon, or pancreatic cancer: a prospective study. <i>European Journal of Heart Failure</i> , <b>2021</b> , 23, 145-153	12.3	6
406	Improvement of Health Status Following Initiation of Sacubitril/Valsartan in Heart Failure and Reduced Ejection Fraction. <i>JACC: Heart Failure</i> , <b>2021</b> , 9, 42-51	7.9	7
405	Effect of Empagliflozin on Cardiovascular and Renal Outcomes in Patients With Heart Failure by Baseline Diabetes Status: Results From the EMPEROR-Reduced Trial. <i>Circulation</i> , <b>2021</b> , 143, 337-349	16.7	80
404	Implications of peripheral oedema in heart failure with preserved ejection fraction: a heart failure network analysis. <i>ESC Heart Failure</i> , <b>2021</b> , 8, 662-669	3.7	2
403	Treatment of HF in an Era of Multiple Therapies: Statement From the HF Collaboratory. <i>JACC: Heart Failure</i> , <b>2021</b> , 9, 1-12	7.9	10
402	The role of sodium glucose co-transporter inhibitors in heart failure prevention. <i>Journal of Diabetes and Its Complications</i> , <b>2021</b> , 35, 107811	3.2	1
401	Trends in Hospitalizations for Heart Failure and Ischemic Heart Disease Among US Adults With Diabetes. <i>JAMA Cardiology</i> , <b>2021</b> , 6, 354-357	16.2	3
400	Discontinuation and non-publication of heart failure randomized controlled trials: a call to publish all trial results. <i>ESC Heart Failure</i> , <b>2021</b> , 8, 16-25	3.7	1
399	The Counter Regulatory Axis of the Lung Renin-Angiotensin System in Severe COVID-19: Pathophysiology and Clinical Implications. <i>Heart Lung and Circulation</i> , <b>2021</b> , 30, 786-794	1.8	8
398	Building a Heart Failure Clinic: A Practical Guide from the Heart Failure Society of America. <i>Journal of Cardiac Failure</i> , <b>2021</b> , 27, 2-19	3.3	5
397	Renin-angiotensin-system inhibition in the context of corona virus disease-19: experimental evidence, observational studies, and clinical implications. <i>Heart Failure Reviews</i> , <b>2021</b> , 26, 381-389	5	4
396	Factors associated with non-use and sub-target dosing of medical therapy for heart failure with reduced ejection fraction. <i>Heart Failure Reviews</i> , <b>2021</b> , 1	5	1
395	Influence of neprilysin inhibition on the efficacy and safety of empagliflozin in patients with chronic heart failure and a reduced ejection fraction: the EMPEROR-Reduced trial. <i>European Heart Journal</i> , <b>2021</b> , 42, 671-680	9.5	36
394	Empagliflozin and health-related quality of life outcomes in patients with heart failure with reduced ejection fraction: the EMPEROR-Reduced trial. <i>European Heart Journal</i> , <b>2021</b> , 42, 1203-1212	9.5	34
393	Sodium glucose co-transporter inhibitors and heart failure outcomes across different patient populations. <i>European Heart Journal</i> , <b>2021</b> ,	9.5	3
392	Challenges and the innovations in the care of advanced heart failure patients during COVID-19. <i>Heart Failure Reviews</i> , <b>2021</b> , 1	5	2
391	INTERVENE-HF: feasibility study of individualized, risk stratification-based, medication intervention in patients with heart failure with reduced ejection fraction. <i>ESC Heart Failure</i> , <b>2021</b> , 8, 849-860	3.7	1
390	Standardizing the standard: reporting health status in clinical trials. <i>European Journal of Heart Failure</i> , <b>2021</b> , 23, 203-204	12.3	

389	Impact of polyvascular disease with and without co-existent kidney dysfunction on cardiovascular outcomes in diabetes: A post hoc analysis of EMPA-REG OUTCOME. <i>Diabetes, Obesity and Metabolism</i> , <b>2021</b> , 23, 1173-1181	6.7	4
388	Functional outcomes with Carillon device over 1 year in patients with functional mitral regurgitation of Grades 2+ to 4+: results from the REDUCE-FMR trial. <i>ESC Heart Failure</i> , <b>2021</b> , 8, 872-878 <sup>3.7</sup>		2
387	Major Depression and Anxiety Among Patients Hospitalized With Heart Failure. <i>American Journal of Cardiology</i> , <b>2021</b> , 142, 153-155	3	0
386	Effect of a Hospital and Postdischarge Quality Improvement Intervention on Clinical Outcomes and Quality of Care for Patients With Heart Failure With Reduced Ejection Fraction: The CONNECT-HF Randomized Clinical Trial. <i>JAMA - Journal of the American Medical Association</i> , <b>2021</b> , 326, 314-323	27.4	8
385	Kidney Function and Outcomes in Patients Hospitalized With Heart Failure. <i>Journal of the American College of Cardiology</i> , <b>2021</b> , 78, 330-343	15.1	14
384	Natriuretic peptide plasma concentrations and risk of cardiovascular versus non-cardiovascular events in heart failure with reduced ejection fraction: Insights from the PARADIGM-HF and ATMOSPHERE trials. <i>American Heart Journal</i> , <b>2021</b> , 237, 45-53	4.9	2
383	Maternal Heart Failure. <i>Journal of the American Heart Association</i> , <b>2021</b> , 10, e021019	6	2
382	Determinants of exercise intolerance symptoms considered non-specific for heart failure in patients with stage A and B: role of the left atrium in the transition phase to overt heart failure. <i>International Journal of Cardiovascular Imaging</i> , <b>2021</b> , 1	2.5	1
381	CARDIOVASCULAR EFFECTS OF NON-INSULIN GLUCOSE-LOWERING AGENTS: A COMPREHENSIVE REVIEW OF TRIAL EVIDENCE AND POTENTIAL CARDIOPROTECTIVE MECHANISMS. <i>Cardiovascular Research</i> , <b>2021</b> ,	9.9	5
380	Iron Deficiency in CKD Without Concomitant Anemia. <i>Kidney International Reports</i> , <b>2021</b> , 6, 2752-2762	4.1	0
379	Effect of Empagliflozin on Worsening Heart Failure Events in Patients With Heart Failure and Preserved Ejection Fraction: EMPEROR-Preserved Trial. <i>Circulation</i> , <b>2021</b> , 144, 1284-1294	16.7	30
378	Empagliflozin in Heart Failure With Predicted Preserved Versus Reduced Ejection Fraction: Data From the EMPA-REG OUTCOME Trial. <i>Journal of Cardiac Failure</i> , <b>2021</b> , 27, 888-895	3.3	4
377	Empagliflozin and Major Renal Outcomes in Heart Failure. <i>New England Journal of Medicine</i> , <b>2021</b> , 385, 1531-1533	59.2	19
376	Hemoglobin and Clinical Outcomes in the Vericiguat Global Study in Patients With Heart Failure and Reduced Ejection Fraction (VICTORIA). <i>Circulation</i> , <b>2021</b> , 144, 1489-1499	16.7	5
375	Empagliflozin in Heart Failure with a Preserved Ejection Fraction. <i>New England Journal of Medicine</i> , <b>2021</b> , 385, 1451-1461	59.2	358
374	Device Therapy in Chronic Heart Failure: JACC State-of-the-Art Review. <i>Journal of the American College of Cardiology</i> , <b>2021</b> , 78, 931-956	15.1	6
373	Novel biomarker-driven prognostic models to predict morbidity and mortality in chronic heart failure: the EMPEROR-Reduced trial. <i>European Heart Journal</i> , <b>2021</b> , 42, 4455-4464	9.5	5
372	2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure. <i>European Heart Journal</i> , <b>2021</b> , 42, 3599-3726	9.5	875



371	Influence of endpoint definitions on the effect of empagliflozin on major renal outcomes in the EMPEROR-Preserved trial. <i>European Journal of Heart Failure</i> , <b>2021</b> , 23, 1798-1799	12.3	4
370	Effects of empagliflozin on insulin initiation or intensification in patients with type 2 diabetes and cardiovascular disease: Findings from the EMPA-REG OUTCOME trial. <i>Diabetes, Obesity and Metabolism</i> , <b>2021</b> , 23, 2775-2784	6.7	2
369	Improvement in Kansas City Cardiomyopathy Questionnaire Scores After a Self-Care Intervention in Patients With Acute Heart Failure Discharged From the Emergency Department. <i>Circulation: Cardiovascular Quality and Outcomes</i> , <b>2021</b> , 14, e007956	5.8	2
368	Sex-Differences in Cause of Death for Patients Hospitalized for Heart Failure With Reduced Versus Preserved Ejection Fraction (from the ASCEND-HF Trial). <i>American Journal of Cardiology</i> , <b>2021</b> , 154, 123-126	3.2	1
367	Prognostic Importance of NT-proBNP and Effect of Empagliflozin in the EMPEROR-Reduced Trial. <i>Journal of the American College of Cardiology</i> , <b>2021</b> , 78, 1321-1332	15.1	10
366	Empagliflozin Improves Cardiovascular and Renal Outcomes in Heart Failure Irrespective of Systolic Blood Pressure. <i>Journal of the American College of Cardiology</i> , <b>2021</b> , 78, 1337-1348	15.1	8
365	Exercise Intolerance in Older Adults With Heart Failure With Preserved Ejection Fraction: JACC State-of-the-Art Review. <i>Journal of the American College of Cardiology</i> , <b>2021</b> , 78, 1166-1187	15.1	17
364	Heart Failure Hospitalization and Guideline-Directed Prescribing Patterns Among Heart Failure With Reduced Ejection Fraction Patients. <i>JACC: Heart Failure</i> , <b>2021</b> , 9, 28-38	7.9	8
363	Clinical Outcomes With Metformin and Sulfonylurea Therapies Among Patients With Heart Failure and Diabetes.. <i>JACC: Heart Failure</i> , <b>2021</b> ,	7.9	4
362	Kidney function assessment and endpoint ascertainment in clinical trials.. <i>European Heart Journal</i> , <b>2021</b> ,	9.5	6
361	Assessment of Heterogeneity in Heart Failure-Related Meta-Analyses. <i>Circulation: Heart Failure</i> , <b>2020</b> , 13, e007070	7.6	2
360	Regulation of Cardiovascular Therapies During the COVID-19 Public Health Emergency. <i>Journal of the American College of Cardiology</i> , <b>2020</b> , 76, 2517-2521	15.1	5
359	Reverse Cardiac Remodeling and Outcome After Initiation of Sacubitril/Valsartan. <i>Circulation: Heart Failure</i> , <b>2020</b> , 13, e006946	7.6	13
358	Risk Profiles in Heart Failure: Baseline, Residual, Worsening, and Advanced Heart Failure Risk. <i>Circulation: Heart Failure</i> , <b>2020</b> , 13, e007132	7.6	11
357	Reductions in Heart Failure Hospitalizations During the COVID-19 Pandemic. <i>Journal of Cardiac Failure</i> , <b>2020</b> , 26, 462-463	3.3	57
356	Empagliflozin in Heart Failure: Diuretic and Cardiorenal Effects. <i>Circulation</i> , <b>2020</b> , 142, 1028-1039	16.7	105
355	Diuretic and renal effects of spironolactone and heart failure hospitalizations: a TOPCAT Americas analysis. <i>European Journal of Heart Failure</i> , <b>2020</b> , 22, 1600-1610	12.3	3
354	Fewer Hospitalizations for Acute Cardiovascular Conditions During the COVID-19 Pandemic. <i>Journal of the American College of Cardiology</i> , <b>2020</b> , 76, 280-288	15.1	110

353	Management of heart failure patients with COVID-19: a joint position paper of the Chinese Heart Failure Association & National Heart Failure Committee and the Heart Failure Association of the European Society of Cardiology. <i>European Journal of Heart Failure</i> , <b>2020</b> , 22, 941-956	12.3	60
352	Extracellular Volume and Global Longitudinal Strain Both Associate With Outcomes But Correlate Minimally. <i>JACC: Cardiovascular Imaging</i> , <b>2020</b> , 13, 2343-2354	8.4	14
351	Hypertensive diseases in pregnancy, cardiac structure and function later in life: Insights from the Genetic Epidemiology Network of Arteriopathy (GENOA) study. <i>Pregnancy Hypertension</i> , <b>2020</b> , 21, 184-190	3.6	1
350	A Meta-analysis of the Relationship Between Renin-Angiotensin-Aldosterone System Inhibitors and COVID-19. <i>American Journal of Cardiology</i> , <b>2020</b> , 130, 159-161	3	14
349	Conducting clinical trials in heart failure during (and after) the COVID-19 pandemic: an Expert Consensus Position Paper from the Heart Failure Association (HFA) of the European Society of Cardiology (ESC). <i>European Heart Journal</i> , <b>2020</b> , 41, 2109-2117	9.5	42
348	Association of Long-term Change and Variability in Glycemia With Risk of Incident Heart Failure Among Patients With Type 2 Diabetes: A Secondary Analysis of the ACCORD Trial. <i>Diabetes Care</i> , <b>2020</b> , 43, 1920-1928	14.6	14
347	Orphan Drug Development in Cardiovascular Medicine. <i>Circulation: Cardiovascular Quality and Outcomes</i> , <b>2020</b> , 13, e006509	5.8	2
346	Pathogenesis of chronic heart failure: cardiovascular aging, risk factors, comorbidities, and disease modifiers. <i>Heart Failure Reviews</i> , <b>2020</b> , 1	5	18
345	Abnormalities of Potassium in Heart Failure: JACC State-of-the-Art Review. <i>Journal of the American College of Cardiology</i> , <b>2020</b> , 75, 2836-2850	15.1	36
344	Comparison of symptomatic and functional responses to vagus nerve stimulation in ANTHEM-HF, INOVATE-HF, and NECTAR-HF. <i>ESC Heart Failure</i> , <b>2020</b> , 7, 75-83	3.7	23
343	Enrollment of Older Patients, Women, and Racial/Ethnic Minority Groups in Contemporary Acute Coronary Syndrome Clinical Trials: A Systematic Review. <i>JAMA Cardiology</i> , <b>2020</b> , 5, 714-722	16.2	29
342	The burden of non-cardiac comorbidities and association with clinical outcomes in an acute heart failure trial—insights from ASCEND-HF. <i>European Journal of Heart Failure</i> , <b>2020</b> , 22, 1022-1031	12.3	11
341	Evaluation of high-sensitivity C-reactive protein and uric acid in vericiguat-treated patients with heart failure with reduced ejection fraction. <i>European Journal of Heart Failure</i> , <b>2020</b> , 22, 1675-1683	12.3	10
340	Vericiguat in Patients with Heart Failure and Reduced Ejection Fraction. <i>New England Journal of Medicine</i> , <b>2020</b> , 382, 1883-1893	59.2	333
339	Comparing the Benefit of Novel Therapies Across Clinical Trials: Insights From the VICTORIA Trial. <i>Circulation</i> , <b>2020</b> , 142, 717-719	16.7	24
338	Management of heart failure and type 2 diabetes mellitus: Maximizing complementary drug therapy. <i>Diabetes, Obesity and Metabolism</i> , <b>2020</b> , 22, 1243-1262	6.7	8
337	Improvement in Left Ventricular Ejection Fraction in Outpatients With Heart Failure With Reduced Ejection Fraction: Data From CHAMP-HF. <i>Circulation: Heart Failure</i> , <b>2020</b> , 13, e006833	7.6	3
336	Racial Differences in Diuretic Efficiency, Plasma Renin, and Rehospitalization in Subjects With Acute Heart Failure. <i>Circulation: Heart Failure</i> , <b>2020</b> , 13, e006827	7.6	7

335	Cardiac magnetic resonance in heart failure with preserved ejection fraction: myocyte, interstitium, microvascular, and metabolic abnormalities. <i>European Journal of Heart Failure</i> , <b>2020</b> , 22, 1065-1075	12.3	17
334	Effects of Elamipretide on Left Ventricular Function in Patients With Heart Failure With Reduced Ejection Fraction: The PROGRESS-HF Phase 2 Trial. <i>Journal of Cardiac Failure</i> , <b>2020</b> , 26, 429-437	3.3	19
333	Adrenoreceptor Autoantibodies in Heart Failure: Physiology and Therapeutic Implications. <i>Circulation: Heart Failure</i> , <b>2020</b> , 13, e006155	7.6	12
332	Low- Versus Moderate-Sodium Diet in Patients With Recent Hospitalization for Heart Failure: The PROHIBIT (Prevent Adverse Outcomes in Heart Failure by Limiting Sodium) Pilot Study. <i>Circulation: Heart Failure</i> , <b>2020</b> , 13, e006389	7.6	6
331	Use of sodium-glucose co-transporter-2 inhibitors in patients with and without type 2 diabetes: implications for incident and prevalent heart failure. <i>European Journal of Heart Failure</i> , <b>2020</b> , 22, 604-617	12.3	22
330	Endpoints in Heart Failure Drug Development: History and Future. <i>JACC: Heart Failure</i> , <b>2020</b> , 8, 429-440	7.9	16
329	Spironolactone metabolite concentrations in decompensated heart failure: insights from the ATHENA-HF trial. <i>European Journal of Heart Failure</i> , <b>2020</b> , 22, 1451-1461	12.3	6
328	Minimal clinically important difference in quality of life scores for patients with heart failure and reduced ejection fraction. <i>European Journal of Heart Failure</i> , <b>2020</b> , 22, 999-1005	12.3	35
327	Contemporary Trends in Prescription of Dipeptidyl Peptidase-4 Inhibitors in the Context of US Food and Drug Administration Warnings of Heart Failure Risk. <i>American Journal of Cardiology</i> , <b>2020</b> , 125, 1577-1581	1	
326	Empagliflozin reduces the risk of mortality and hospitalization for heart failure across Thrombolysis In Myocardial Infarction Risk Score for Heart Failure in Diabetes categories: Post hoc analysis of the EMPA-REG OUTCOME trial. <i>Diabetes, Obesity and Metabolism</i> , <b>2020</b> , 22, 1141-1150	6.7	9
325	Ultrafiltration in Acute Heart Failure: Implications of Ejection Fraction and Early Response to Treatment From CARRESS-HF. <i>Journal of the American Heart Association</i> , <b>2020</b> , 9, e015752	6	5
324	How well do we represent ourselves: an analysis of cardiology fellowships website content. <i>Future Cardiology</i> , <b>2020</b> , 16, 281-287	1.3	8
323	The inadequacy of cardiovascular safety reporting in breast cancer clinical trials.. <i>Journal of Clinical Oncology</i> , <b>2020</b> , 38, e24100-e24100	2.2	
322	Contribution of individual components to composite end points in contemporary cardiovascular randomized controlled trials. <i>American Heart Journal</i> , <b>2020</b> , 230, 71-81	4.9	0
321	Contemporary Treatment Patterns and Clinical Outcomes of Comorbid Diabetes Mellitus and HFrEF: The CHAMP-HF Registry. <i>JACC: Heart Failure</i> , <b>2020</b> , 8, 469-480	7.9	16
320	Diastolic Dysfunction in Patients With Human Immunodeficiency Virus Receiving Antiretroviral Therapy: Results From the CHART Study. <i>Journal of Cardiac Failure</i> , <b>2020</b> , 26, 371-380	3.3	10
319	Serum ST2 and hospitalization rates in Caucasian and African American outpatients with heart failure. <i>International Journal of Cardiology</i> , <b>2020</b> , 304, 116-121	3.2	2
318	Left atrial function in heart failure with preserved ejection fraction: a systematic review and meta-analysis. <i>European Journal of Heart Failure</i> , <b>2020</b> , 22, 472-485	12.3	28

317	Prescription drug spending and hospital use among Medicare beneficiaries with heart failure. <i>Research in Social and Administrative Pharmacy</i> , <b>2020</b> , 16, 1452-1458	2.9	1
316	Biomarker Profile of Left Atrial Myopathy in Heart Failure With Preserved Ejection Fraction: Insights From the RELAX Trial. <i>Journal of Cardiac Failure</i> , <b>2020</b> , 26, 270-275	3.3	6
315	Variation in Placebo Effect on Health-Related Quality of Life in Heart Failure (from the TOPCAT Trial). <i>American Journal of Cardiology</i> , <b>2020</b> , 125, 82-86	3	1
314	Post-discharge haemodilution, congestion, and clinical outcomes among patients hospitalized for heart failure with reduced ejection fraction: results from the EVEREST trial. <i>European Journal of Heart Failure</i> , <b>2020</b> , 22, 164-167	12.3	2
313	Acutely decompensated versus acute heart failure: two different entities. <i>Heart Failure Reviews</i> , <b>2020</b> , 25, 907-916	5	4
312	Insulin-like Growth Factor Binding Protein 2 predicts mortality risk in heart failure. <i>International Journal of Cardiology</i> , <b>2020</b> , 300, 245-251	3.2	7
311	N-Terminal Pro-B-Type Natriuretic Peptide and Clinical Outcomes: Vericiguat Heart Failure With Reduced Ejection Fraction Study. <i>JACC: Heart Failure</i> , <b>2020</b> , 8, 931-939	7.9	30
310	Effect of Vericiguat vs Placebo on Quality of Life in Patients With Heart Failure and Preserved Ejection Fraction: The VITALITY-HFpEF Randomized Clinical Trial. <i>JAMA - Journal of the American Medical Association</i> , <b>2020</b> , 324, 1512-1521	27.4	71
309	Cigarette Smoking and Incident Stroke in Blacks of the Jackson Heart Study. <i>Journal of the American Heart Association</i> , <b>2020</b> , 9, e014990	6	10
308	Real-Life Multimarker Monitoring in Patients with Heart Failure: Continuous Remote Monitoring of Mobility and Patient-Reported Outcomes as Digital End Points in Future Heart-Failure Trials. <i>Digital Biomarkers</i> , <b>2020</b> , 4, 45-59	7.1	6
307	Cause of Death in Patients With Acute Heart Failure: Insights From RELAX-AHF-2. <i>JACC: Heart Failure</i> , <b>2020</b> , 8, 999-1008	7.9	0
306	Design of a prospective patient-level pooled analysis of two parallel trials of empagliflozin in patients with established heart failure. <i>European Journal of Heart Failure</i> , <b>2020</b> , 22, 2393-2398	12.3	9
305	Ferric carboxymaltose for iron deficiency at discharge after acute heart failure: a multicentre, double-blind, randomised, controlled trial. <i>Lancet, The</i> , <b>2020</b> , 396, 1895-1904	40	162
304	Baseline characteristics of patients with heart failure with preserved ejection fraction in the EMPEROR-Preserved trial. <i>European Journal of Heart Failure</i> , <b>2020</b> , 22, 2383-2392	12.3	41
303	Clinical effects of cardiac contractility modulation in heart failure with mildly reduced systolic function. <i>ESC Heart Failure</i> , <b>2020</b> , 7, 3531	3.7	6
302	Benefit-Risk Tradeoffs in Assessment of New Drugs and Devices. <i>Circulation</i> , <b>2020</b> , 142, 1974-1988	16.7	2
301	Clinical and Economic Burden of Chronic Heart Failure and Reduced Ejection Fraction Following a Worsening Heart Failure Event. <i>Advances in Therapy</i> , <b>2020</b> , 37, 4015-4032	4.1	15
300	Representation of Women Authors in International Heart Failure Guidelines and Contemporary Clinical Trials. <i>Circulation: Heart Failure</i> , <b>2020</b> , 13, e006605	7.6	27

299	Cardiac Imaging in Dialysis Patients. <i>Kidney Medicine</i> , <b>2020</b> , 2, 629-638	2.8	2
298	Application of the Reverse Fragility Index to Statistically Nonsignificant Randomized Clinical Trial Results. <i>JAMA Network Open</i> , <b>2020</b> , 3, e2012469	10.4	14
297	Relation of Low Normal Left Ventricular Ejection Fraction to Heart Failure Hospitalization in Blacks (From the Jackson Heart Study). <i>American Journal of Cardiology</i> , <b>2020</b> , 136, 100-106	3	1
296	Effects of Canagliflozin on Amino-Terminal Pro-B-Type Natriuretic Peptide: Implications for Cardiovascular Risk Reduction. <i>Journal of the American College of Cardiology</i> , <b>2020</b> , 76, 2076-2085	15.1	19
295	Victims of Success in Failure. <i>Circulation</i> , <b>2020</b> , 142, 1129-1131	16.7	8
294	Ten lessons from the EMPEROR-Reduced trial. <i>European Journal of Heart Failure</i> , <b>2020</b> , 22, 1991-1993	12.3	1
293	Glucagon-Like Peptide 1 Receptor Agonists and Heart Failure: The Need for Further Evidence Generation and Practice Guidelines Optimization. <i>Circulation</i> , <b>2020</b> , 142, 1205-1218	16.7	16
292	Cardiovascular and Renal Outcomes with Empagliflozin in Heart Failure. <i>New England Journal of Medicine</i> , <b>2020</b> , 383, 1413-1424	59.2	1099
291	SGLT2 inhibitors in patients with heart failure with reduced ejection fraction: a meta-analysis of the EMPEROR-Reduced and DAPA-HF trials. <i>Lancet, The</i> , <b>2020</b> , 396, 819-829	40	355
290	Non-insulin antihyperglycaemic drugs and heart failure: an overview of current evidence from randomized controlled trials. <i>ESC Heart Failure</i> , <b>2020</b> , 7, 3438	3.7	6
289	Totality of evidence in trials of sodium-glucose co-transporter-2 inhibitors in the patients with heart failure with reduced ejection fraction: implications for clinical practice. <i>European Heart Journal</i> , <b>2020</b> , 41, 3398-3401	9.5	14
288	Clinical Associations of Vascular Stiffness, Microvascular Dysfunction, and Prevalent Cardiovascular Disease in a Black Cohort: The Jackson Heart Study. <i>Journal of the American Heart Association</i> , <b>2020</b> , 9, e017018	6	4
287	Medicaid Expansion and Utilization of Antihyperglycemic Therapies. <i>Diabetes Care</i> , <b>2020</b> , 43, 2684-2690	14.6	3
286	Antihyperglycemic Therapies With Expansions of US Food and Drug Administration Indications to Reduce Cardiovascular Events: Prescribing Patterns Within an Academic Medical Center. <i>Journal of Cardiovascular Pharmacology</i> , <b>2020</b> , 76, 313-320	3.1	14
285	Challenges and Potential Improvements to Patient Access to Pharmaceuticals: Examples From Cardiology. <i>Circulation</i> , <b>2020</b> , 142, 790-798	16.7	3
284	Cardiovascular implications of COVID-19 versus influenza infection: a review. <i>BMC Medicine</i> , <b>2020</b> , 18, 403	11.4	18
283	Salt, No Salt, or Less Salt for Patients With Heart Failure?. <i>American Journal of Medicine</i> , <b>2020</b> , 133, 32-38	2.4	12
282	Trends in Aggregate Use and Associated Expenditures of Antihyperglycemic Therapies Among US Medicare Beneficiaries Between 2012 and 2017. <i>JAMA Internal Medicine</i> , <b>2020</b> , 180, 141-144	11.5	14

281	Care Optimization Through Patient and Hospital Engagement Clinical Trial for Heart Failure: Rationale and design of CONNECT-HF. <i>American Heart Journal</i> , <b>2020</b> , 220, 41-50	4.9	13
280	Trends in prevalence of comorbidities in heart failure clinical trials. <i>European Journal of Heart Failure</i> , <b>2020</b> , 22, 1032-1042	12.3	18
279	From PARADIGM to PARAGON further evidence supporting continuous heart failure spectrum. <i>European Journal of Heart Failure</i> , <b>2020</b> , 22, 1536-1539	12.3	2
278	Applicability of US Food and Drug Administration Labeling for Dapagliflozin to Patients With Heart Failure With Reduced Ejection Fraction in US Clinical Practice: The Get With the Guidelines-Heart Failure (GWTG-HF) Registry. <i>JAMA Cardiology</i> , <b>2020</b> ,	16.2	8
277	Efficacy and safety of SGLT2 inhibitors in heart failure: systematic review and meta-analysis. <i>ESC Heart Failure</i> , <b>2020</b> , 7, 3298-3309	3.7	26
276	Trends in prevalence of comorbidities in heart failure clinical trials <b>2020</b> , 22, 1032		1
275	Primary Prevention of Heart Failure in Patients With Type 2 Diabetes Mellitus. <i>Circulation</i> , <b>2019</b> , 139, 152-154	16.7	12
274	Haemoconcentration during treatment of acute heart failure with cardiorenal syndrome: from the CARESS-HF trial. <i>European Journal of Heart Failure</i> , <b>2019</b> , 21, 1472-1476	12.3	1
273	Association of Change in N-Terminal Pro-B-Type Natriuretic Peptide Following Initiation of Sacubitril-Valsartan Treatment With Cardiac Structure and Function in Patients With Heart Failure With Reduced Ejection Fraction. <i>JAMA - Journal of the American Medical Association</i> , <b>2019</b> , 322, 1085-1095	27.4	199
272	Association Between Sacubitril/Valsartan Initiation and Health Status Outcomes in Heart Failure With Reduced Ejection Fraction. <i>JACC: Heart Failure</i> , <b>2019</b> , 7, 933-941	7.9	24
271	Redefining Heart Failure With a Reduced Ejection Fraction. <i>JAMA - Journal of the American Medical Association</i> , <b>2019</b> , 322, 1761-1762	27.4	27
270	Efficacy of Neurohormonal Therapies in Preventing Cardiotoxicity in Patients with Cancer Undergoing Chemotherapy. <i>JACC: CardioOncology</i> , <b>2019</b> , 1, 54-65	3.8	39
269	Association between long-term adherence to class-I recommended medications and risk for potentially preventable heart failure hospitalizations among younger adults. <i>PLoS ONE</i> , <b>2019</b> , 14, e0222868	3.7	4
268	Empagliflozin Improves Kidney Outcomes in Patients With or Without Heart Failure. <i>Circulation: Heart Failure</i> , <b>2019</b> , 12, e005875	7.6	30
267	Rationale and Design of the VITALITY-HFpEF Trial. <i>Circulation: Heart Failure</i> , <b>2019</b> , 12, e005998	7.6	22
266	Assessment of Heart Failure in Diabetes Cardiovascular Outcomes Trials: Is What We Are Currently Capturing Adequate?. <i>Current Diabetes Reports</i> , <b>2019</b> , 19, 39	5.6	3
265	Prescription Drug Spending and Medication Adherence Among Medicare Beneficiaries with Heart Failure. <i>Journal of Managed Care &amp; Specialty Pharmacy</i> , <b>2019</b> , 25, 705-713	1.9	7
264	Sodium Zirconium Cyclosilicate among Individuals with Hyperkalemia: A 12-Month Phase 3 Study. <i>Clinical Journal of the American Society of Nephrology: CJASN</i> , <b>2019</b> , 14, 798-809	6.9	64

263	Titration of Medical Therapy for Heart Failure With Reduced Ejection Fraction. <i>Journal of the American College of Cardiology</i> , <b>2019</b> , 73, 2365-2383	15.1	147
262	Novel potassium binders as enabling therapy in heart failure. <i>European Journal of Heart Failure</i> , <b>2019</b> , 21, 550-552	12.3	3
261	Heart failure prevention with sodium-glucose cotransporter 2 inhibitors. <i>Journal of Diabetes</i> , <b>2019</b> , 11, 601-604	3.8	1
260	Extended prophylaxis for venous thromboembolism after hospitalization for medical illness: A trial sequential and cumulative meta-analysis. <i>PLoS Medicine</i> , <b>2019</b> , 16, e1002797	11.6	20
259	Relation Between Cigarette Smoking and Heart Failure (from the Multiethnic Study of Atherosclerosis). <i>American Journal of Cardiology</i> , <b>2019</b> , 123, 1972-1977	3	7
258	New treatments for hyperkalaemia: clinical use in cardiology. <i>European Heart Journal Supplements</i> , <b>2019</b> , 21, A41-A47	1.5	3
257	Early Treatment in Emergency Department Patients with Acute Heart Failure: Does Time Matter?. <i>Current Heart Failure Reports</i> , <b>2019</b> , 16, 12-20	2.8	0
256	Prescription of Glucagon-Like Peptide-1 Receptor Agonists by Cardiologists. <i>Journal of the American College of Cardiology</i> , <b>2019</b> , 73, 1596-1598	15.1	23
255	Empagliflozin Is Associated With a Lower Risk of Post-Acute Heart Failure Rehospitalization and Mortality. <i>Circulation</i> , <b>2019</b> , 139, 1458-1460	16.7	34
254	Barriers to guideline mandated renin-angiotensin inhibitor use: focus on hyperkalaemia. <i>European Heart Journal Supplements</i> , <b>2019</b> , 21, A20-A27	1.5	7
253	The continuous heart failure spectrum: moving beyond an ejection fraction classification. <i>European Heart Journal</i> , <b>2019</b> , 40, 2155-2163	9.5	107
252	Prognostic Implications of Changes in Amino-Terminal Pro-B-Type Natriuretic Peptide in Acute Decompensated Heart Failure: Insights From ASCEND-HF. <i>Journal of Cardiac Failure</i> , <b>2019</b> , 25, 703-711	3.3	6
251	Clinical Course of Patients With Worsening Heart Failure With Reduced Ejection Fraction. <i>Journal of the American College of Cardiology</i> , <b>2019</b> , 73, 935-944	15.1	63
250	Do Women and Men Respond Similarly to Therapies in Contemporary Heart Failure Clinical Trials?. <i>JACC: Heart Failure</i> , <b>2019</b> , 7, 267-271	7.9	9
249	Commentary: Failure predicting failure: The right ventricle after left ventricular assist device implantation. <i>Journal of Thoracic and Cardiovascular Surgery</i> , <b>2019</b> , 157, 1861-1862	1.5	1
248	Spironolactone in Acute Heart Failure Patients With Renal Dysfunction and Risk Factors for Diuretic Resistance: From the ATHENA-HF Trial. <i>Canadian Journal of Cardiology</i> , <b>2019</b> , 35, 1097-1105	3.8	14
247	Financial Hardship From Medical Bills Among Nonelderly U.S. Adults With Atherosclerotic Cardiovascular Disease. <i>Journal of the American College of Cardiology</i> , <b>2019</b> , 73, 727-732	15.1	33
246	Physical Activity, Quality of Life, and Biomarkers in Atrial Fibrillation and Heart Failure With Preserved Ejection Fraction (from the NEAT-HFpEF Trial). <i>American Journal of Cardiology</i> , <b>2019</b> , 123, 1660-1666	3	4

245	Why Clinicians Should Care About the Cardiac Interstitium. <i>JACC: Cardiovascular Imaging</i> , <b>2019</b> , 12, 2305-2318	10
244	Design of a "Lean" Case Report Form for Heart Failure Therapeutic Development. <i>JACC: Heart Failure</i> , <b>2019</b> , 7, 913-921	7.9 3
243	Cardiovascular Aging and Heart Failure: JACC Review Topic of the Week. <i>Journal of the American College of Cardiology</i> , <b>2019</b> , 74, 804-813	15.1 73
242	Timely Management of New-Onset Heart Failure. <i>Circulation</i> , <b>2019</b> , 140, 621-623	16.7 7
241	Evaluation of the effect of sodium-glucose co-transporter 2 inhibition with empagliflozin on morbidity and mortality of patients with chronic heart failure and a reduced ejection fraction: rationale for and design of the EMPEROR-Reduced trial. <i>European Journal of Heart Failure</i> , <b>2019</b> , 21, 1270-1278	12.3 73
240	Clinical aspects of heart failure in individuals with diabetes. <i>Diabetologia</i> , <b>2019</b> , 62, 1529-1538	10.3 9
239	Evaluation of the effects of sodium-glucose co-transporter 2 inhibition with empagliflozin on morbidity and mortality in patients with chronic heart failure and a preserved ejection fraction: rationale for and design of the EMPEROR-Preserved Trial. <i>European Journal of Heart Failure</i> , <b>2019</b> , 21, 1279-1287	12.3 133
238	Representativeness of a Heart Failure Trial by Race and Sex: Results From ASCEND-HF and GWTG-HF. <i>JACC: Heart Failure</i> , <b>2019</b> , 7, 980-992	7.9 11
237	Diagnosis and Prevention of Hypertensive Heart Failure. <i>Heart Failure Clinics</i> , <b>2019</b> , 15, 435-445	3.3 5
236	Unraveling the Molecular Mechanism of Action of Empagliflozin in Heart Failure With Reduced Ejection Fraction With/Without Diabetes. <i>JACC Basic To Translational Science</i> , <b>2019</b> , 4, 831-840	8.7 42
235	Comparison of Hydralazine/Nitrate and Angiotensin Receptor Neprilysin Inhibitor Use Among Black Versus Nonblack Americans With Heart Failure and Reduced Ejection Fraction (from CHAMP-HF). <i>American Journal of Cardiology</i> , <b>2019</b> , 124, 1900-1906	3 8
234	Incorporation of Biomarkers Into Risk Assessment for Allocation of Antihypertensive Medication According to the 2017 ACC/AHA High Blood Pressure Guideline: A Pooled Cohort Analysis. <i>Circulation</i> , <b>2019</b> , 140, 2076-2088	16.7 23
233	Safety and efficacy of the partial adenosine A1 receptor agonist neladenoson bialanate in patients with chronic heart failure with reduced ejection fraction: a phase IIb, randomized, double-blind, placebo-controlled trial. <i>European Journal of Heart Failure</i> , <b>2019</b> , 21, 1426-1433	12.3 19
232	Reply: Titration of Guideline-Directed Medical Therapy Improves Patient-Centered Outcomes in Heart Failure With Reduced Ejection Fraction. <i>Journal of the American College of Cardiology</i> , <b>2019</b> , 74, 1426-1427	15.1 2
231	Sodium-Glucose Cotransporter-2 Inhibitors and Heart Failure Prevention in Type 2 Diabetes. <i>Cardiac Failure Review</i> , <b>2019</b> , 5, 169-172	4.2 1
230	The Limitations of Symptom-based Heart Failure Management. <i>Cardiac Failure Review</i> , <b>2019</b> , 5, 74-77	4.2 4
229	Impact of Autonomic Regulation Therapy in Patients with Heart Failure: ANTHEM-HFrEF Pivotal Study Design. <i>Circulation: Heart Failure</i> , <b>2019</b> , 12, e005879	7.6 21
228	Machine Learning to Predict the Risk of Incident Heart Failure Hospitalization Among Patients With Diabetes: The WATCH-DM Risk Score. <i>Diabetes Care</i> , <b>2019</b> , 42, 2298-2306	14.6 70



227	Identifying responders to oral iron supplementation in heart failure with a reduced ejection fraction: a post-hoc analysis of the IRONOUT-HF trial. <i>Journal of Cardiovascular Medicine</i> , <b>2019</b> , 20, 223-228	19	9
226	SGLT-2 inhibitors in heart failure: a new therapeutic avenue. <i>Nature Medicine</i> , <b>2019</b> , 25, 1653-1654	50.5	3
225	Heart Failure End Points in Cardiovascular Outcome Trials of Sodium Glucose Cotransporter 2 Inhibitors in Patients With Type 2 Diabetes Mellitus: A Critical Evaluation of Clinical and Regulatory Issues. <i>Circulation</i> , <b>2019</b> , 140, 2108-2118	16.7	13
224	Therapeutic Advances in the Management of Acute Decompensated Heart Failure. <i>American Journal of Therapeutics</i> , <b>2019</b> , 26, e222-e233	1	3
223	Predictors of heart failure development in type 2 diabetes: a practical approach. <i>Current Opinion in Cardiology</i> , <b>2019</b> , 34, 578-583	2.1	9
222	Baseline features of the VICTORIA (Vericiguat Global Study in Subjects with Heart Failure with Reduced Ejection Fraction) trial. <i>European Journal of Heart Failure</i> , <b>2019</b> , 21, 1596-1604	12.3	35
221	Therapeutic Advances in the Management of Cardiogenic Shock. <i>American Journal of Therapeutics</i> , <b>2019</b> , 26, e234-e247	1	8
220	Adrenomedullin in heart failure: pathophysiology and therapeutic application. <i>European Journal of Heart Failure</i> , <b>2019</b> , 21, 163-171	12.3	69
219	Initiation, Continuation, Switching, and Withdrawal of Heart Failure Medical Therapies During Hospitalization. <i>JACC: Heart Failure</i> , <b>2019</b> , 7, 1-12	7.9	51
218	Relation of Living in a "Food Desert" to Recurrent Hospitalizations in Patients With Heart Failure. <i>American Journal of Cardiology</i> , <b>2019</b> , 123, 291-296	3	22
217	Heart Failure Epidemiology in Patients With Diabetes Mellitus Without Coronary Heart Disease. <i>Journal of Cardiac Failure</i> , <b>2019</b> , 25, 78-86	3.3	13
216	Cardiomyopathy and Heart Failure in Patients With HIV Infection. <i>Canadian Journal of Cardiology</i> , <b>2019</b> , 35, 299-309	3.8	16
215	History of Atrial Fibrillation and Trajectory of Decongestion in Acute Heart Failure. <i>JACC: Heart Failure</i> , <b>2019</b> , 7, 47-55	7.9	6
214	Medication dosing for heart failure with reduced ejection fraction - opportunities and challenges. <i>European Journal of Heart Failure</i> , <b>2019</b> , 21, 286-296	12.3	32
213	Updates on Device-Based Therapies for Patients with Heart Failure. <i>Current Heart Failure Reports</i> , <b>2018</b> , 15, 53-60	2.8	5
212	Comorbidities, Sociodemographic Factors, and Hospitalizations in Outpatients With Heart Failure and Preserved Ejection Fraction. <i>American Journal of Cardiology</i> , <b>2018</b> , 121, 1207-1213	3	12
211	Diastolic Dysfunction in Individuals With Human Immunodeficiency Virus Infection: Literature Review, Rationale and Design of the Characterizing Heart Function on Antiretroviral Therapy (CHART) Study. <i>Journal of Cardiac Failure</i> , <b>2018</b> , 24, 255-265	3.3	22
210	Multiple Avenues of Modulating the Nitric Oxide Pathway in Heart Failure Clinical Trials. <i>Current Heart Failure Reports</i> , <b>2018</b> , 15, 44-52	2.8	9

209	Determinants of Diuretic Responsiveness and Associated Outcomes During Acute Heart Failure Hospitalization: An Analysis From the NHLBI Heart Failure Network Clinical Trials. <i>Journal of Cardiac Failure</i> , <b>2018</b> , 24, 428-438	3.3	18
208	Glucose-Lowering Therapies and Heart Failure in Type 2 Diabetes Mellitus: Mechanistic Links, Clinical Data, and Future Directions. <i>Circulation</i> , <b>2018</b> , 137, 1060-1073	16.7	20
207	Effects of Exercise on ASC Methylation and IL-1 Cytokines in Heart Failure. <i>Medicine and Science in Sports and Exercise</i> , <b>2018</b> , 50, 1757-1766	1.2	19
206	Association of Biomarker Clusters With Cardiac Phenotypes and Mortality in Patients With HIV Infection. <i>Circulation: Heart Failure</i> , <b>2018</b> , 11, e004312	7.6	26
205	Health Status Variation Across Practices in Outpatients With Heart Failure: Insights From the CHAMP-HF (Change the Management of Patients With Heart Failure) Registry. <i>Circulation: Cardiovascular Quality and Outcomes</i> , <b>2018</b> , 11, e004668	5.8	13
204	Myocardial Interstitial Fibrosis in Heart Failure: Biological and Translational Perspectives. <i>Journal of the American College of Cardiology</i> , <b>2018</b> , 71, 1696-1706	15.1	204
203	Effects of empagliflozin on risk for cardiovascular death and heart failure hospitalization across the spectrum of heart failure risk in the EMPA-REG OUTCOME <sup>2</sup> trial. <i>European Heart Journal</i> , <b>2018</b> , 39, 363-370	9.5	171
202	Systemic inflammation and functional capacity in elderly heart failure patients. <i>Clinical Research in Cardiology</i> , <b>2018</b> , 107, 362-367	6.1	14
201	Evolving Landscape of Clinical Trials in Heart Failure: Patient Populations, Endpoint Selection, and Regions of Enrollment. <i>Current Heart Failure Reports</i> , <b>2018</b> , 15, 10-16	2.8	5
200	Globalization of heart failure clinical trials: a systematic review of 305 trials conducted over 16 years. <i>European Journal of Heart Failure</i> , <b>2018</b> , 20, 1068-1071	12.3	11
199	Exploring heart failure events in contemporary cardiovascular outcomes trials in type 2 diabetes mellitus. <i>Expert Review of Cardiovascular Therapy</i> , <b>2018</b> , 16, 123-131	2.5	
198	Myocardial Energetics and Heart Failure: a Review of Recent Therapeutic Trials. <i>Current Heart Failure Reports</i> , <b>2018</b> , 15, 191-197	2.8	8
197	Is Time of the Essence? The Impact of Time of Hospital Presentation in Acute Heart Failure: Insights From ASCEND-HF Trial. <i>JACC: Heart Failure</i> , <b>2018</b> , 6, 298-307	7.9	2
196	Expanded algorithm for managing patients with acute decompensated heart failure. <i>Heart Failure Reviews</i> , <b>2018</b> , 23, 597-607	5	4
195	Prevalent and Incident Heart Failure in Cardiovascular Outcome Trials of Patients With Type 2 Diabetes. <i>Journal of the American College of Cardiology</i> , <b>2018</b> , 71, 1379-1390	15.1	43
194	A Multicenter, Randomized, Double-Blind, Placebo-Controlled Trial of the Efficacy and Safety of the Oral Soluble Guanylate Cyclase Stimulator: The VICTORIA Trial. <i>JACC: Heart Failure</i> , <b>2018</b> , 6, 96-104	7.9	83
193	Pre-discharge and early post-discharge troponin elevation among patients hospitalized for heart failure with reduced ejection fraction: findings from the ASTRONAUT trial. <i>European Journal of Heart Failure</i> , <b>2018</b> , 20, 281-291	12.3	17
192	Rationale of the FIBROTARGETS study designed to identify novel biomarkers of myocardial fibrosis. <i>ESC Heart Failure</i> , <b>2018</b> , 5, 139-148	3.7	14

191	Past, present, and future of acute heart failure clinical trials-a high-risk population in search of a strategy. <i>European Journal of Heart Failure</i> , <b>2018</b> , 20, 839-841	12.3	3
190	Medical Therapy for Heart Failure With Reduced Ejection Fraction: The CHAMP-HF Registry. <i>Journal of the American College of Cardiology</i> , <b>2018</b> , 72, 351-366	15.1	333
189	Design Elements and Enrollment Patterns of Contemporary Trials in Heart Failure With Preserved Ejection Fraction: A Systematic Review. <i>JACC: Heart Failure</i> , <b>2018</b> , 6, 714-717	7.9	3
188	FP071 SAFETY AND EFFICACY OF SODIUM ZIRCONIUM CYCLOSILICATE FOR LONG-TERM TREATMENT OF HYPERKALAEMIA IN PATIENTS WITH CHRONIC KIDNEY DISEASE: RESULTS FROM AN OPEN-LABEL, PHASE 3 STUDY. <i>Nephrology Dialysis Transplantation</i> , <b>2018</b> , 33, i72-i72	4.3	3
187	Sudden Death After Hospitalization for Heart Failure With Reduced Ejection Fraction (from the EVEREST Trial). <i>American Journal of Cardiology</i> , <b>2018</b> , 122, 255-260	3	4
186	Definitions of Stage D heart failure and outcomes among outpatients with heart failure and reduced ejection fraction. <i>International Journal of Cardiology</i> , <b>2018</b> , 272, 250-254	3.2	3
185	Antihyperglycemic Therapies to Treat Patients With Heart Failure and Diabetes Mellitus. <i>JACC: Heart Failure</i> , <b>2018</b> , 6, 813-822	7.9	20
184	Enrollment of Older Patients, Women, and Racial and Ethnic Minorities in Contemporary Heart Failure Clinical Trials: A Systematic Review. <i>JAMA Cardiology</i> , <b>2018</b> , 3, 1011-1019	16.2	79
183	Questioning the Associations of Omega-3 Fatty Acid Supplement Use With Cardiovascular Disease Risks. <i>JAMA Cardiology</i> , <b>2018</b> , 3, 781	16.2	1
182	Characteristics and Treatments of Patients Enrolled in the CHAMP-HF Registry Compared With Patients Enrolled in the PARADIGM-HF Trial. <i>Journal of the American Heart Association</i> , <b>2018</b> , 7,	6	18
181	Need to revisit heart failure treatment guidelines for hyperkalemia management during the use of mineralocorticoid receptor antagonists. <i>European Journal of Heart Failure</i> , <b>2018</b> , 20, 1247-1251	12.3	12
180	Mobile health applications in cardiovascular research. <i>International Journal of Cardiology</i> , <b>2018</b> , 269, 265-271	3.7	13
179	Rationale and Design of a Prospective, Multicenter, Observational Study Evaluating Iron Deficiency in Patients Hospitalized for Heart Failure (FERIC-RO). <i>Romanian Journal of Laboratory Medicine</i> , <b>2018</b> , 26, 271-281	0.3	1
178	Acute Dyspnea and Decompensated Heart Failure. <i>Cardiology Clinics</i> , <b>2018</b> , 36, 63-72	2.5	8
177	Availability and Use of Shared Data From Cardiometabolic Clinical Trials. <i>Circulation</i> , <b>2018</b> , 137, 938-947	16.7	8
176	Optimal Endpoints of Acute Heart Failure Therapy. <i>American Journal of Therapeutics</i> , <b>2018</b> , 25, e465-e474		3
175	A new educational program in heart failure drug development: the Brescia international master program. <i>Journal of Cardiovascular Medicine</i> , <b>2018</b> , 19, 411-421	1.9	7
174	Relationship between timing of trial randomization, protocol completion, and clinical outcomes among patients hospitalized for heart failure: from the ASTRONAUT trial. <i>European Journal of Heart Failure</i> , <b>2018</b> , 20, 1760-1763	12.3	2

173	The Vulnerable Phase of Heart Failure. <i>American Journal of Therapeutics</i> , <b>2018</b> , 25, e456-e464	1	8
172	Association Between Regional Adipose Tissue Distribution and Risk of Heart Failure Among Blacks. <i>Circulation: Heart Failure</i> , <b>2018</b> , 11, e005629	7.6	15
171	Prescriber Patterns of SGLT2i After Expansions of U.S. Food and Drug Administration Labeling. <i>Journal of the American College of Cardiology</i> , <b>2018</b> , 72, 3370-3372	15.1	61
170	Circulating Cardiac Troponin I Levels Measured by a Novel Highly Sensitive Assay in Acute Decompensated Heart Failure: Insights From the ASCEND-HF Trial. <i>Journal of Cardiac Failure</i> , <b>2018</b> , 24, 512-519	3.3	7
169	Relationship Between Enrolling Country Income Level and Patient Profile, Protocol Completion, and Trial End Points. <i>Circulation: Cardiovascular Quality and Outcomes</i> , <b>2018</b> , 11, e004783	5.8	7
168	Improving Postdischarge Outcomes in Acute Heart Failure. <i>American Journal of Therapeutics</i> , <b>2018</b> , 25, e475-e486	1	6
167	Patient, Provider, and Practice Characteristics Associated With Sacubitril/Valsartan Use in the United States. <i>Circulation: Heart Failure</i> , <b>2018</b> , 11, e005400	7.6	28
166	Reassessing the Role of Surrogate End Points in Drug Development for Heart Failure. <i>Circulation</i> , <b>2018</b> , 138, 1039-1053	16.7	13
165	A Critical Appraisal of Short-Term End Points in Acute Heart Failure Clinical Trials. <i>Journal of Cardiac Failure</i> , <b>2018</b> , 24, 783-792	3.3	6
164	Revisiting hyperkalaemia guidelines: rebuttal. <i>European Journal of Heart Failure</i> , <b>2018</b> , 20, 1255	12.3	1
163	Rationale and design of the phase 2b clinical trials to study the effects of the partial adenosine A1-receptor agonist neladenoson bialanate in patients with chronic heart failure with reduced (PANTHEON) and preserved (PANACHE) ejection fraction. <i>European Journal of Heart Failure</i> , <b>2018</b> , 20, 1601-1610	12.3	20
162	Cost-Effectiveness Analysis of Patiromer and Spironolactone Therapy in Heart Failure Patients with Hyperkalemia. <i>Pharmacoeconomics</i> , <b>2018</b> , 36, 1463-1473	4.4	11
161	Treatment of Diabetes in Patients with Heart Failure. <i>Current Cardiology Reports</i> , <b>2018</b> , 20, 97	4.2	
160	Coronary microvascular dysfunction in patients with heart failure with preserved ejection fraction. <i>American Journal of Physiology - Heart and Circulatory Physiology</i> , <b>2018</b> , 314, H1033-H1042	5.2	57
159	Mihai Gheorghiade, MD-Life and Concepts. <i>American Journal of Therapeutics</i> , <b>2018</b> , 25, e453-e455	1	
158	Nomenclature in heart failure: a call for objective, reproducible, and biologically-driven terminology. <i>European Journal of Heart Failure</i> , <b>2018</b> , 20, 1379-1381	12.3	5
157	The Current Landscape of Atrial Fibrillation and Atrial Flutter Clinical Trials: A Report of 348 Studies Registered With ClinicalTrials.gov. <i>JACC: Clinical Electrophysiology</i> , <b>2018</b> , 4, 944-954	4.6	4
156	Association between funding sources and the scope and outcomes of cardiovascular clinical trials: A systematic review. <i>International Journal of Cardiology</i> , <b>2017</b> , 230, 301-303	3.2	5

155	SPECT and PET in ischemic heart failure. <i>Heart Failure Reviews</i> , <b>2017</b> , 22, 243-261	5	14
154	Heart failure guidelines: What's new?. <i>Trends in Cardiovascular Medicine</i> , <b>2017</b> , 27, 316-323	6.9	4
153	Mode of Death in Heart Failure With Preserved Ejection Fraction. <i>Journal of the American College of Cardiology</i> , <b>2017</b> , 69, 556-569	15.1	135
152	High-density lipoprotein-associated paraoxonase-1 activity for prediction of adverse outcomes in outpatients with chronic heart failure. <i>European Journal of Heart Failure</i> , <b>2017</b> , 19, 748-755	12.3	21
151	Design and Rationale of a Randomized Trial of a Care Transition Strategy in Patients With Acute Heart Failure Discharged From the Emergency Department: GUIDED-HF (Get With the Guidelines in Emergency Department Patients With Heart Failure). <i>Circulation: Heart Failure</i> , <b>2017</b> , 10,	7.6	13
150	Role of Hyperkalemia in Heart Failure and the Therapeutic Use of Potassium Binders. <i>Handbook of Experimental Pharmacology</i> , <b>2017</b> , 243, 537-560	3.2	8
149	Change the management of patients with heart failure: Rationale and design of the CHAMP-HF registry. <i>American Heart Journal</i> , <b>2017</b> , 189, 177-183	4.9	32
148	Risk for Incident Heart Failure: A Subject-Level Meta-Analysis From the Heart "OMics" in AGEing (HOMAGE) Study. <i>Journal of the American Heart Association</i> , <b>2017</b> , 6,	6	27
147	2017 ACC/AHA/HFSA Focused Update of the 2013 ACCF/AHA Guideline for the Management of Heart Failure: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines and the Heart Failure Society of America. <i>Circulation</i> , <b>2017</b> ,	16.7	1503
146	2017 ACC/AHA/HFSA Focused Update of the 2013 ACCF/AHA Guideline for the Management of Heart Failure: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines and the Heart Failure Society of America. <i>Journal of the American College of Cardiology</i> , <b>2017</b> , 70, 776-803	15.1	1064
145	Influence of atrial fibrillation on post-discharge natriuretic peptide trajectory and clinical outcomes among patients hospitalized for heart failure: insights from the ASTRONAUT trial. <i>European Journal of Heart Failure</i> , <b>2017</b> , 19, 552-562	12.3	19
144	Progression to Stage D Heart Failure Among Outpatients With Stage C Heart Failure and Reduced Ejection Fraction. <i>JACC: Heart Failure</i> , <b>2017</b> , 5, 528-537	7.9	29
143	Employing Extracellular Volume Cardiovascular Magnetic Resonance Measures of Myocardial Fibrosis to Foster Novel Therapeutics. <i>Circulation: Cardiovascular Imaging</i> , <b>2017</b> , 10,	3.9	33
142	Hospitalization for Recently Diagnosed Versus Worsening Chronic Heart Failure: From the ASCEND-HF Trial. <i>Journal of the American College of Cardiology</i> , <b>2017</b> , 69, 3029-3039	15.1	41
141	Patient-reported outcomes in the SOLuble guanylate Cyclase stimulator in heArT failurE patientS with PRESERVED ejection fraction (SOCRATES-PRESERVED) study. <i>European Journal of Heart Failure</i> , <b>2017</b> , 19, 782-791	12.3	54
140	Effects of Canagliflozin on Cardiovascular Biomarkers in Older Adults With Type 2 Diabetes. <i>Journal of the American College of Cardiology</i> , <b>2017</b> , 70, 704-712	15.1	106
139	Vericiguat in patients with worsening chronic heart failure and preserved ejection fraction: results of the SOLuble guanylate Cyclase stimulator in heArT failurE patientS with PRESERVED EF (SOCRATES-PRESERVED) study. <i>European Heart Journal</i> , <b>2017</b> , 38, 1119-1127	9.5	192
138	Drug Development for Heart Failure With Preserved Ejection Fraction: What Pieces Are Missing From the Puzzle?. <i>Canadian Journal of Cardiology</i> , <b>2017</b> , 33, 768-776	3.8	8

137	Reassessing Phase II Heart Failure Clinical Trials: Consensus Recommendations. <i>Circulation: Heart Failure</i> , <b>2017</b> , 10,	7.6	11
136	Glycaemic control in heart failure: a PARADIGM shift for patients with concomitant diabetes?. <i>Lancet Diabetes and Endocrinology</i> , <b>2017</b> , 5, 314-315	18.1	7
135	Expert consensus document: Mitochondrial function as a therapeutic target in heart failure. <i>Nature Reviews Cardiology</i> , <b>2017</b> , 14, 238-250	14.8	322
134	Body Weight Change During and After Hospitalization for Acute Heart Failure: Patient Characteristics, Markers of Congestion, and Outcomes: Findings From the ASCEND-HF Trial. <i>JACC: Heart Failure</i> , <b>2017</b> , 5, 1-13	7.9	58
133	The Cardio-Renal Interrelationship. <i>Progress in Cardiovascular Diseases</i> , <b>2017</b> , 59, 636-648	8.5	27
132	Heart Rate and Outcomes in Hospitalized Patients With Heart Failure With Preserved Ejection Fraction. <i>Journal of the American College of Cardiology</i> , <b>2017</b> , 70, 1861-1871	15.1	22
131	The Ethics of Conducting Clinical Trials With Sodium-Glucose Cotransporter-2 Inhibitors in Heart Failure: Is Placebo Assignment Justified in Patients With Comorbid Diabetes Mellitus and Heart Failure?. <i>Circulation</i> , <b>2017</b> , 136, 1459-1461	16.7	5
130	Contemporary Epidemiology, Management, and Outcomes of Patients Hospitalized for Heart Failure in China: Results From the China Heart Failure (China-HF) Registry. <i>Journal of Cardiac Failure</i> , <b>2017</b> , 23, 868-875	3.3	64
129	The potential role and rationale for treatment of heart failure with sodium-glucose co-transporter 2 inhibitors. <i>European Journal of Heart Failure</i> , <b>2017</b> , 19, 1390-1400	12.3	111
128	Postmarketing Adverse Events Related to the CardioMEMS HF System. <i>JAMA Cardiology</i> , <b>2017</b> , 2, 1277-1279	12.9	33
127	A Scientific Analysis of the 100 Citation Classics of Valvular Heart Disease. <i>American Journal of Cardiology</i> , <b>2017</b> , 120, 1440-1449	3	22
126	Temporal Relation Between Myocardial Fibrosis and Heart Failure With Preserved Ejection Fraction: Association With Baseline Disease Severity and Subsequent Outcome. <i>JAMA Cardiology</i> , <b>2017</b> , 2, 995-1006	16.2	107
125	Effects of Sodium-Glucose Cotransporter 2 Inhibitors for the Treatment of Patients With Heart Failure: Proposal of a Novel Mechanism of Action. <i>JAMA Cardiology</i> , <b>2017</b> , 2, 1025-1029	16.2	217
124	Impact of Site Selection and Study Conduct on Outcomes in Global Clinical Trials. <i>Current Heart Failure Reports</i> , <b>2017</b> , 14, 203-209	2.8	1
123	Dose of Angiotensin-Converting Enzyme Inhibitors and Angiotensin Receptor Blockers and Outcomes in Heart Failure: A Meta-Analysis. <i>Circulation: Heart Failure</i> , <b>2017</b> , 10,	7.6	26
122	Waiting Period Before Implantable Cardioverter-Defibrillator Implantation in Newly Diagnosed Heart Failure With Reduced Ejection Fraction: A Window of Opportunity. <i>Circulation: Heart Failure</i> , <b>2017</b> , 10,	7.6	12
121	Incorporating Patient and Caregiver Experiences Into Cardiovascular Clinical Trial Design. <i>JAMA Cardiology</i> , <b>2017</b> , 2, 1263-1269	16.2	8
120	Novel Endpoints for Heart Failure Clinical Trials. <i>Current Heart Failure Reports</i> , <b>2017</b> , 14, 210-216	2.8	7

119	Efficacy and Safety of Spironolactone in Acute Heart Failure: The ATHENA-HF Randomized Clinical Trial. <i>JAMA Cardiology</i> , <b>2017</b> , 2, 950-958	16.2	114
118	Designing Future Clinical Trials in Heart Failure With Preserved Ejection Fraction: Lessons From TOPCAT. <i>Current Heart Failure Reports</i> , <b>2017</b> , 14, 217-222	2.8	11
117	Exercise Capacity, Heart Failure Risk, and Mortality in Older Adults: The Health ABC Study. <i>American Journal of Preventive Medicine</i> , <b>2017</b> , 52, 144-153	6.1	9
116	Intravenous Allogeneic Mesenchymal Stem Cells for Nonischemic Cardiomyopathy: Safety and Efficacy Results of a Phase II-A Randomized Trial. <i>Circulation Research</i> , <b>2017</b> , 120, 332-340	15.7	105
115	Atrial fibrillation in heart failure with preserved ejection fraction: Insights into mechanisms and therapeutics. <i>Pharmacology &amp; Therapeutics</i> , <b>2017</b> , 176, 32-39	13.9	35
114	Safety and Tolerability of Neladenoson Bialanate, a Novel Oral Partial Adenosine A1 Receptor Agonist, in Patients With Chronic Heart Failure. <i>Journal of Clinical Pharmacology</i> , <b>2017</b> , 57, 440-451	2.9	33
113	Leadership in cardiology. <i>European Heart Journal</i> , <b>2017</b> , 38, 2323	9.5	
112	The Three-Decade Long Journey in Heart Failure Drug Development. <i>Handbook of Experimental Pharmacology</i> , <b>2017</b> , 243, 1-14	3.2	6
111	Platelet-Derived Growth Factor in Heart Failure. <i>Handbook of Experimental Pharmacology</i> , <b>2017</b> , 243, 355-369	3.2	9
110	Hot Topics in Primary Care: Cardiovascular Safety of Medications for Type 2 Diabetes Mellitus. <i>Journal of Family Practice</i> , <b>2017</b> , 66, S16-S21	0.2	3
109	Echocardiography in Acute Heart Failure: Current Perspectives. <i>Journal of Cardiac Failure</i> , <b>2016</b> , 22, 82-94.	3	18
108	Intensification of Medication Therapy for Cardiorenal Syndrome in Acute Decompensated Heart Failure. <i>Journal of Cardiac Failure</i> , <b>2016</b> , 22, 26-32	3.3	34
107	Temporal trends and factors associated with diabetes mellitus among patients hospitalized with heart failure: Findings from Get With The Guidelines-Heart Failure registry. <i>American Heart Journal</i> , <b>2016</b> , 182, 9-20	4.9	72
106	Exploring New Endpoints for Patients With Heart Failure With Preserved Ejection Fraction. <i>Circulation: Heart Failure</i> , <b>2016</b> , 9,	7.6	36
105	Global left atrial failure in heart failure. <i>European Journal of Heart Failure</i> , <b>2016</b> , 18, 1307-1320	12.3	59
104	Pregnant women with heart disease: Placental characteristics and their association with fetal adverse events. <i>Acute Cardiac Care</i> , <b>2016</b> , 18, 56-64		7
103	Clinical and Research Considerations for Patients With Hypertensive Acute Heart Failure: A Consensus Statement from the Society of Academic Emergency Medicine and the Heart Failure Society of America Acute Heart Failure Working Group. <i>Journal of Cardiac Failure</i> , <b>2016</b> , 22, 618-27	3.3	1
102	Precipitating Clinical Factors, Heart Failure Characterization, and Outcomes in Patients Hospitalized With Heart Failure With Reduced, Borderline, and Preserved Ejection Fraction. <i>JACC: Heart Failure</i> , <b>2016</b> , 4, 464-72	7.9	133

101	Baseline and long-term gamma-glutamyltransferase, heart failure and cardiac arrhythmias in middle-aged Finnish men: Prospective study and pooled analysis of published evidence. <i>European Journal of Preventive Cardiology</i> , <b>2016</b> , 23, 1354-62	3.9	22
100	Sudden cardiac death in heart failure with preserved ejection fraction: a target for therapy?. <i>Heart Failure Reviews</i> , <b>2016</b> , 21, 455-62	5	21
99	Serum Osmolality and Postdischarge Outcomes After Hospitalization for Heart Failure. <i>American Journal of Cardiology</i> , <b>2016</b> , 117, 1144-50	3	16
98	Cancer Therapy-Related Cardiac Dysfunction and Heart Failure: Part 1: Definitions, Pathophysiology, Risk Factors, and Imaging. <i>Circulation: Heart Failure</i> , <b>2016</b> , 9, e002661	7.6	156
97	Prognostic significance of (123)I-MIBG SPECT myocardial imaging in heart failure: differences between patients with ischaemic and non-ischaemic heart failure. <i>European Heart Journal Cardiovascular Imaging</i> , <b>2016</b> , 17, 384-90	4.1	17
96	Spot urine sodium excretion as prognostic marker in acutely decompensated heart failure: the spironolactone effect. <i>Clinical Research in Cardiology</i> , <b>2016</b> , 105, 489-507	6.1	26
95	Trends in Utilization of Surrogate Endpoints in Contemporary Cardiovascular Clinical Trials. <i>American Journal of Cardiology</i> , <b>2016</b> , 117, 1845-50	3	8
94	Coenzyme Q10 and Heart Failure: A State-of-the-Art Review. <i>Circulation: Heart Failure</i> , <b>2016</b> , 9, e002639	7.6	77
93	Utility of Patient-Reported Outcome Instruments in Heart Failure. <i>JACC: Heart Failure</i> , <b>2016</b> , 4, 165-75	7.9	82
92	Partial adenosine A1 receptor agonism: a potential new therapeutic strategy for heart failure. <i>Heart Failure Reviews</i> , <b>2016</b> , 21, 95-102	5	44
91	The Right Ventricular Function After Left Ventricular Assist Device (RVF-LVAD) study: rationale and preliminary results. <i>European Heart Journal Cardiovascular Imaging</i> , <b>2016</b> , 17, 429-37	4.1	20
90	Trends in Heart Failure Clinical Trials From 2001-2012. <i>Journal of Cardiac Failure</i> , <b>2016</b> , 22, 171-9	3.3	13
89	Cancer Therapy-Related Cardiac Dysfunction and Heart Failure: Part 2: Prevention, Treatment, Guidelines, and Future Directions. <i>Circulation: Heart Failure</i> , <b>2016</b> , 9, e002843	7.6	84
88	Temporal Changes in Postdischarge Mortality Risk After Hospitalization for Heart Failure (from the EVEREST Trial). <i>American Journal of Cardiology</i> , <b>2016</b> , 117, 611-616	3	11
87	Clinical Effectiveness of Hydralazine-Isosorbide Dinitrate Therapy in Patients With Heart Failure and Reduced Ejection Fraction: Findings From the Get With The Guidelines-Heart Failure Registry. <i>Circulation: Heart Failure</i> , <b>2016</b> , 9, e002444	7.6	14
86	Methylation of Apoptosis-Associated Speck-Like Protein With a Caspase Recruitment Domain and Outcomes in Heart Failure. <i>Journal of Cardiac Failure</i> , <b>2016</b> , 22, 340-6	3.3	13
85	Utility of positron emission tomography for drug development for heart failure. <i>American Heart Journal</i> , <b>2016</b> , 175, 142-52	4.9	7
84	Association between resistin levels and cardiovascular disease events in older adults: The health, aging and body composition study. <i>Atherosclerosis</i> , <b>2016</b> , 245, 181-6	3.1	41



83	Assessing the Risk of Progression From Asymptomatic Left Ventricular Dysfunction to Overt Heart Failure: A Systematic Overview and Meta-Analysis. <i>JACC: Heart Failure</i> , <b>2016</b> , 4, 237-48	7.9	58
82	Effects of Polyunsaturated Fatty Acid Treatment on Postdischarge Outcomes After Acute Myocardial Infarction. <i>American Journal of Cardiology</i> , <b>2016</b> , 117, 340-6	3	12
81	Clinical and Research Considerations for Patients With Hypertensive Acute Heart Failure: A Consensus Statement from the Society for Academic Emergency Medicine and the Heart Failure Society of America Acute Heart Failure Working Group. <i>Academic Emergency Medicine</i> , <b>2016</b> , 23, 922-31	3.4	7
80	Contrasting acute and chronic effects of tolvaptan on serum osmolality in the EVEREST trial. <i>European Journal of Heart Failure</i> , <b>2016</b> , 18, 185-91	12.3	7
79	Renal function estimation and Cockcroft-Gault formulas for predicting cardiovascular mortality in population-based, cardiovascular risk, heart failure and post-myocardial infarction cohorts: The Heart Failure and Atrial Fibrillation in Aging (HOMAGE) and the high-risk myocardial infarction database initiatives. <i>BMC Medicine</i> , <b>2016</b> , 14, 181	11.4	35
78	Biomarkers and Cancer Therapy-Related Cardiac Dysfunction. <i>Current Cardiovascular Risk Reports</i> , <b>2016</b> , 10, 1	0.9	
77	Cardiovascular clinical trials with noninferiority or equivalence designs from 2001 to 2012. <i>International Journal of Cardiology</i> , <b>2016</b> , 214, 16-8	3.2	2
76	Renal biomarkers and outcomes in outpatients with heart failure: The Atlanta cardiomyopathy consortium. <i>International Journal of Cardiology</i> , <b>2016</b> , 218, 136-143	3.2	4
75	New approaches to hyperkalemia in patients with indications for renin angiotensin aldosterone inhibitors: Considerations for trial design and regulatory approval. <i>International Journal of Cardiology</i> , <b>2016</b> , 216, 46-51	3.2	19
74	2016 ACC/AHA/HFSA Focused Update on New Pharmacological Therapy for Heart Failure: An Update of the 2013 ACCF/AHA Guideline for the Management of Heart Failure: A Report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and the Heart Failure Society of America. <i>Journal of the American College of Cardiology</i>	15.1	452
73	How to Best Identify Elderly Individuals Who May Develop Heart Failure. <i>Current Cardiovascular Risk Reports</i> , <b>2016</b> , 10, 1	0.9	
72	Atrial Fibrillation and Declining Physical Performance in Older Adults: The Health, Aging, and Body Composition Study. <i>Circulation: Arrhythmia and Electrophysiology</i> , <b>2016</b> , 9, e003525	6.4	29
71	Elevated Soluble Fms-Like Tyrosine Kinase-1 and Placental-Like Growth Factor Levels Are Associated With Development and Mortality Risk in Heart Failure. <i>Circulation: Heart Failure</i> , <b>2016</b> , 9, e002115	7.6	27
70	Hyperkalemia in Heart Failure. <i>Journal of the American College of Cardiology</i> , <b>2016</b> , 68, 1575-89	15.1	60
69	Transforming Drug Development in Heart Failure: Navigating the Regulatory Crossroads. <i>Circulation: Heart Failure</i> , <b>2016</b> , 9,	7.6	8
68	Influence of Clinical Trial Site Enrollment on Patient Characteristics, Protocol Completion, and End Points: Insights From the ASCEND-HF Trial (Acute Study of Clinical Effectiveness of Nesiritide in Decompensated Heart Failure). <i>Circulation: Heart Failure</i> , <b>2016</b> , 9,	7.6	10
67	Reframing the association and significance of co-morbidities in heart failure. <i>European Journal of Heart Failure</i> , <b>2016</b> , 18, 744-58	12.3	116
66	Dose response characterization of the association of serum digoxin concentration with mortality outcomes in the Digitalis Investigation Group trial. <i>European Journal of Heart Failure</i> , <b>2016</b> , 18, 1072-81	12.3	30

65	Rationale and Design of the ATHENA-HF Trial: Aldosterone Targeted Neurohormonal Combined With Natriuresis Therapy in Heart Failure. <i>JACC: Heart Failure</i> , <b>2016</b> , 4, 726-35	7.9	27
64	Spectrum of epidemiological and clinical findings in patients with heart failure with preserved ejection fraction stratified by study design: a systematic review. <i>European Journal of Heart Failure</i> , <b>2016</b> , 18, 54-65	12.3	57
63	Contemporary Drug Development in Heart Failure: Call for Hemodynamically Neutral Therapies. <i>Circulation: Heart Failure</i> , <b>2015</b> , 8, 826-31	7.6	28
62	Using Natriuretic Peptides for Selection of Patients in Acute Heart Failure Clinical Trials. <i>American Journal of Cardiology</i> , <b>2015</b> , 116, 1304-10	3	3
61	Improved Outcomes for Women on the Heart Transplant Wait List in the Modern Era. <i>Journal of Cardiac Failure</i> , <b>2015</b> , 21, 555-60	3.3	21
60	Validation of clinical scores for right ventricular failure prediction after implantation of continuous-flow left ventricular assist devices. <i>Journal of Heart and Lung Transplantation</i> , <b>2015</b> , 34, 1595-603	5.8	74
59	Blood urea nitrogen to creatinine ratio is associated with congestion and mortality in heart failure patients with renal dysfunction. <i>Internal and Emergency Medicine</i> , <b>2015</b> , 10, 965-72	3.7	22
58	Trends in characteristics of cardiovascular clinical trials 2001-2012. <i>American Heart Journal</i> , <b>2015</b> , 170, 263-72	4.9	23
57	Association of Physical Activity or Fitness With Incident Heart Failure: A Systematic Review and Meta-Analysis. <i>Circulation: Heart Failure</i> , <b>2015</b> , 8, 853-61	7.6	38
56	An economic evaluation of a self-care intervention in persons with heart failure and diabetes. <i>Journal of Cardiac Failure</i> , <b>2015</b> , 21, 730-7	3.3	11
55	Resting heart rate and risk of incident heart failure: three prospective cohort studies and a systematic meta-analysis. <i>Journal of the American Heart Association</i> , <b>2015</b> , 4, e001364	6	37
54	Randomized clinical trial of an integrated self-care intervention for persons with heart failure and diabetes: quality of life and physical functioning outcomes. <i>Journal of Cardiac Failure</i> , <b>2015</b> , 21, 719-29	3.3	38
53	Improving cardiovascular clinical trials conduct in the United States: recommendation from clinicians, researchers, sponsors, and regulators. <i>American Heart Journal</i> , <b>2015</b> , 169, 305-14	4.9	18
52	The potential role of natriuretic peptide-guided management for patients hospitalized for heart failure. <i>Journal of Cardiac Failure</i> , <b>2015</b> , 21, 233-9	3.3	13
51	Patient selection in heart failure with preserved ejection fraction clinical trials. <i>Journal of the American College of Cardiology</i> , <b>2015</b> , 65, 1668-1682	15.1	89
50	Advanced (stage D) heart failure: a statement from the Heart Failure Society of America Guidelines Committee. <i>Journal of Cardiac Failure</i> , <b>2015</b> , 21, 519-34	3.3	195
49	Antecedents of self-care in adults with congenital heart defects. <i>International Journal of Cardiology</i> , <b>2015</b> , 201, 610-5	3.2	18
48	Effect of Vericiguat, a Soluble Guanylate Cyclase Stimulator, on Natriuretic Peptide Levels in Patients With Worsening Chronic Heart Failure and Reduced Ejection Fraction: The SOCRATES-REDUCED Randomized Trial. <i>JAMA - Journal of the American Medical Association</i> , <b>2015</b> , 314, 2251-62	27.4	188

47	Concomitant diabetes mellitus and heart failure. <i>Current Problems in Cardiology</i> , <b>2015</b> , 40, 7-43	17.1	54
46	Heart failure at the crossroads: moving beyond blaming stakeholders to targeting the heart. <i>European Journal of Heart Failure</i> , <b>2015</b> , 17, 760-3	12.3	14
45	Length of hospital stay and 30-day readmission following heart failure hospitalization: insights from the EVEREST trial. <i>European Journal of Heart Failure</i> , <b>2015</b> , 17, 1022-31	12.3	40
44	Role of biomarkers in cardiac structure phenotyping in heart failure with preserved ejection fraction: critical appraisal and practical use. <i>European Journal of Heart Failure</i> , <b>2015</b> , 17, 1231-9	12.3	59
43	Comparing Sodium Intake Strategies in Heart Failure: Rationale and Design of the Prevent Adverse Outcomes in Heart Failure by Limiting Sodium (PROHIBIT) Study. <i>Circulation: Heart Failure</i> , <b>2015</b> , 8, 636-45	7.6	16
42	The Importance of NLRP3 Inflammasome in Heart Failure. <i>Journal of Cardiac Failure</i> , <b>2015</b> , 21, 586-93	3.3	70
41	Contemporary cardiovascular device clinical trials (trends and patterns 2001 to 2012). <i>American Journal of Cardiology</i> , <b>2015</b> , 116, 307-12	3	2
40	Impact of Heart Disease on Maternal and Fetal Outcomes in Pregnant Women. <i>American Journal of Cardiology</i> , <b>2015</b> , 116, 474-80	3	17
39	Population risk prediction models for incident heart failure: a systematic review. <i>Circulation: Heart Failure</i> , <b>2015</b> , 8, 438-47	7.6	40
38	Hypertonic Saline in Conjunction with High-Dose Furosemide Improves Dose-Response Curves in Worsening Refractory Congestive Heart Failure. <i>Advances in Therapy</i> , <b>2015</b> , 32, 971-82	4.1	16
37	Myocardial Fibrosis Quantified by Extracellular Volume Is Associated With Subsequent Hospitalization for Heart Failure, Death, or Both Across the Spectrum of Ejection Fraction and Heart Failure Stage. <i>Journal of the American Heart Association</i> , <b>2015</b> , 4,	6	119
36	Advance directives among hospitalized patients with heart failure. <i>JACC: Heart Failure</i> , <b>2015</b> , 3, 112-21	7.9	57
35	The vulnerable phase after hospitalization for heart failure. <i>Nature Reviews Cardiology</i> , <b>2015</b> , 12, 220-9	14.8	129
34	Impact of diabetes on epidemiology, treatment, and outcomes of patients with heart failure. <i>JACC: Heart Failure</i> , <b>2015</b> , 3, 136-45	7.9	190
33	Heart failure therapeutics on the basis of a biased ligand of the angiotensin-2 type 1 receptor. Rationale and design of the BLAST-AHF study (Biased Ligand of the Angiotensin Receptor Study in Acute Heart Failure). <i>JACC: Heart Failure</i> , <b>2015</b> , 3, 193-201	7.9	62
32	Therapeutic targets in heart failure: refocusing on the myocardial interstitium. <i>Journal of the American College of Cardiology</i> , <b>2014</b> , 63, 2188-98	15.1	90
31	The global health and economic burden of hospitalizations for heart failure: lessons learned from hospitalized heart failure registries. <i>Journal of the American College of Cardiology</i> , <b>2014</b> , 63, 1123-1133	15.1	1160
30	The effects of androgen deprivation therapy on cardiac function and heart failure: implications for management of prostate cancer. <i>Clinical Genitourinary Cancer</i> , <b>2014</b> , 12, 399-407	3.3	16

29	Clinical profile and prognostic value of anemia at the time of admission and discharge among patients hospitalized for heart failure with reduced ejection fraction: findings from the EVEREST trial. <i>Circulation: Heart Failure</i> , <b>2014</b> , 7, 401-8	7.6	27
28	Effect of spironolactone on 30-day death and heart failure rehospitalization (from the COACH Study). <i>American Journal of Cardiology</i> , <b>2014</b> , 114, 737-42	3	44
27	Current perspectives on hydralazine and nitrate therapies in heart failure. <i>Heart Failure Clinics</i> , <b>2014</b> , 10, 565-76	3.3	4
26	Effect of serelaxin on mode of death in acute heart failure: results from the RELAX-AHF study. <i>Journal of the American College of Cardiology</i> , <b>2014</b> , 64, 1591-8	15.1	50
25	Efficacy and safety of high dose versus low dose furosemide with or without dopamine infusion: the Dopamine in Acute Decompensated Heart Failure II (DAD-HF II) trial. <i>International Journal of Cardiology</i> , <b>2014</b> , 172, 115-21	3.2	77
24	Association of electrocardiogram abnormalities and incident heart failure events. <i>American Heart Journal</i> , <b>2014</b> , 167, 869-75.e3	4.9	11
23	Inotrope use and outcomes among patients hospitalized for heart failure: impact of systolic blood pressure, cardiac index, and etiology. <i>Journal of Cardiac Failure</i> , <b>2014</b> , 20, 593-601	3.3	11
22	Designing effective drug and device development programs for hospitalized heart failure: a proposal for pretrial registries. <i>American Heart Journal</i> , <b>2014</b> , 168, 142-9	4.9	25
21	Noncardiac comorbidities in heart failure with reduced versus preserved ejection fraction. <i>Journal of the American College of Cardiology</i> , <b>2014</b> , 64, 2281-93	15.1	313
20	Recognizing worsening chronic heart failure as an entity and an end point in clinical trials. <i>JAMA - Journal of the American Medical Association</i> , <b>2014</b> , 312, 789-90	27.4	42
19	Response to Sexton: Inhibiting the renin-angiotensin-aldosterone system in patients with heart failure and renal dysfunction: common sense or nonsense?. <i>Circulation: Heart Failure</i> , <b>2014</b> , 7, 537-40	7.6	3
18	Management of comorbid diabetes mellitus and worsening heart failure. <i>JAMA - Journal of the American Medical Association</i> , <b>2014</b> , 311, 2379-80	27.4	39
17	High-sensitivity C-reactive protein in acute heart failure: insights from the ASCEND-HF trial. <i>Journal of Cardiac Failure</i> , <b>2014</b> , 20, 319-26	3.3	37
16	Coronary artery disease in patients with heart failure: incidental, coincidental, or a target for therapy?. <i>American Journal of Medicine</i> , <b>2014</b> , 127, 574-8	2.4	2
15	2013 ACCF/AHA guideline for the management of heart failure: a report of the American College of Cardiology Foundation/American Heart Association Task Force on practice guidelines. <i>Circulation</i> , <b>2013</b> , 128, e240-327	16.7	1927
14	Nitrate therapy for heart failure: benefits and strategies to overcome tolerance. <i>JACC: Heart Failure</i> , <b>2013</b> , 1, 183-91	7.9	25
13	Forecasting the impact of heart failure in the United States: a policy statement from the American Heart Association. <i>Circulation: Heart Failure</i> , <b>2013</b> , 6, 606-19	7.6	1613
12	2013 ACCF/AHA guideline for the management of heart failure: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. <i>Journal of the American College of Cardiology</i> , <b>2013</b> , 62, e147-239	15.1	4318

11	Strategies and opportunities for drug development in heart failure. <i>JAMA - Journal of the American Medical Association</i> , <b>2013</b> , 309, 1593-4	27.4	34
10	Low-dose dopamine or low-dose nesiritide in acute heart failure with renal dysfunction: the ROSE acute heart failure randomized trial. <i>JAMA - Journal of the American Medical Association</i> , <b>2013</b> , 310, 2533-43	27.4	322
9	Need for increased awareness and evidence-based therapies for patients hospitalized for heart failure. <i>JAMA - Journal of the American Medical Association</i> , <b>2013</b> , 310, 2035-6	27.4	29
8	Update on aldosterone antagonists use in heart failure with reduced left ventricular ejection fraction. Heart Failure Society of America Guidelines Committee. <i>Journal of Cardiac Failure</i> , <b>2012</b> , 18, 265-81	3.3	42
7	Echocardiography, natriuretic peptides, and risk for incident heart failure in older adults: the Cardiovascular Health Study. <i>JACC: Cardiovascular Imaging</i> , <b>2012</b> , 5, 131-40	8.4	36
6	Epidemiology of incident heart failure in a contemporary elderly cohort: the health, aging, and body composition study. <i>Archives of Internal Medicine</i> , <b>2009</b> , 169, 708-15		135
5	Relation of the metabolic syndrome to quantity of coronary atherosclerotic plaque. <i>American Journal of Cardiology</i> , <b>2008</b> , 101, 1127-30	3	19
4	Incident heart failure prediction in the elderly: the health ABC heart failure score. <i>Circulation: Heart Failure</i> , <b>2008</b> , 1, 125-33	7.6	182
3	Comparison of multidetector computed tomography and two-dimensional transthoracic echocardiography for left ventricular assessment in patients with heart failure. <i>American Journal of Cardiology</i> , <b>2007</b> , 99, 247-9	3	49
2	Extent and distribution of coronary artery disease: a comparative study of invasive versus noninvasive angiography with computed angiography. <i>American Heart Journal</i> , <b>2007</b> , 153, 378-84	4.9	39
1	Outcomes with empagliflozin in heart failure with preserved ejection fraction using DELIVER-like endpoint definitions. <i>European Journal of Heart Failure</i> ,	12.3	4